Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 10, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | HVBC | |
Entity Registrant Name | HV Bancorp, Inc. | |
Entity Central Index Key | 0001594555 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity File Number | 001-37981 | |
Entity Tax Identification Number | 46-4351868 | |
Entity Address, Address Line One | 2005 South Easton Road | |
Entity Address, Address Line Two | Suite 304 | |
Entity Address, City or Town | Doylestown | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 18901 | |
City Area Code | 267 | |
Local Phone Number | 280-4000 | |
Entity Common Stock, Shares Outstanding | 2,240,613 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Incorporation, State or Country Code | PA | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | Common Stock, $0.01 par value | |
Security Exchange Name | NASDAQ |
Consolidated Statements of Fina
Consolidated Statements of Financial Condition - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Assets | ||
Cash and due from banks | $ 2,025 | $ 1,473 |
Interest-earning deposits with banks | 14,492 | 19,152 |
Federal funds sold | 3,998 | |
Cash and cash equivalents | 20,515 | 20,625 |
Investment securities available-for-sale, at fair value | 23,200 | 21,156 |
Equity securities | 500 | 500 |
Loans held for sale, at fair value | 37,368 | 37,876 |
Loans receivable, net of allowance for loan losses of $1,549 at March 31, 2020 and $1,437 at December 31, 2019 | 252,704 | 255,032 |
Bank-owned life insurance | 6,293 | 6,255 |
Restricted investment in bank stock | 1,751 | 1,552 |
Premises and equipment, net | 2,618 | 2,501 |
Operating lease right-of-use assets | 6,187 | 5,979 |
Accrued interest receivable | 1,112 | 967 |
Mortgage banking derivatives | 2,236 | 1,204 |
Other assets | 1,102 | 939 |
Total Assets | 355,586 | 354,586 |
Liabilities | ||
Deposits | 278,185 | 283,767 |
Advances from the Federal Home Loan Bank | 32,000 | 27,000 |
Operating lease liabilities | 6,296 | 6,023 |
Advances from borrowers for taxes and insurance | 1,936 | 2,138 |
Deferred income taxes, net | 317 | 97 |
Other liabilities | 3,039 | 1,962 |
Total Liabilities | 321,773 | 320,987 |
Shareholders’ Equity | ||
Preferred Stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and December 31, 2019 | ||
Common Stock, $0.01 par value, 20,000,000 shares authorized; 2,270,725 and 2,269,125 shares issued as of March 31, 2020 and December 31, 2019, respectively; 2,259,052 and 2,268,917 shares outstanding as of March 31, 2020 and December 31, 2019, respectively | 23 | 23 |
Treasury Stock, at cost (11,673 shares at March 31, 2020 and 208 shares December 31, 2019) | (148) | (3) |
Additional paid-in capital | 20,831 | 20,740 |
Retained earnings | 15,122 | 14,973 |
Accumulated other comprehensive income (loss) | 71 | (18) |
Unearned Employee Stock Option Plan | (2,086) | (2,116) |
Total Shareholders' Equity | 33,813 | 33,599 |
Total Liabilities and Shareholders' Equity | $ 355,586 | $ 354,586 |
Consolidated Statements of Fi_2
Consolidated Statements of Financial Condition (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Statement Of Financial Position [Abstract] | ||
Loans receivable, allowance for loan losses | $ 1,549 | $ 1,437 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 20,000,000 | 20,000,000 |
Common stock, shares issued | 2,270,725 | 2,269,125 |
Common stock, shares outstanding | 2,259,052 | 2,268,917 |
Treasury stock, shares | 11,673 | 208 |
Unaudited Consolidated Statemen
Unaudited Consolidated Statements of Income - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Interest Income | ||
Interest and fees on loans | $ 2,776,000 | $ 2,330,000 |
Interest and dividends on investments: | ||
Taxable | 96,000 | 109,000 |
Nontaxable | 11,000 | 72,000 |
Interest on mortgage-backed securities and collateralized mortgage obligations | 53,000 | 102,000 |
Interest on interest-earning deposits and federal funds sold | 90,000 | 115,000 |
Total Interest Income | 3,026,000 | 2,728,000 |
Interest Expense | ||
Interest on deposits | 777,000 | 689,000 |
Interest on advances from the Federal Home Loan Bank | 156,000 | 45,000 |
Interest on securities sold under agreements to repurchase | 1,000 | |
Total Interest Expense | 933,000 | 735,000 |
Net interest income | 2,093,000 | 1,993,000 |
Provision for Loan Losses | 111,000 | 241,000 |
Net interest income after provision for loan losses | 1,982,000 | 1,752,000 |
Non-Interest Income | ||
Fees for customer services | 39,000 | 30,000 |
Increase in cash surrender value of bank-owned life insurance | 38,000 | 39,000 |
Gain on sale of loans, net | 1,629,000 | 890,000 |
Gain on sale of available-for-sale securities, net | 4,000 | |
Gain from derivative instruments, net | 384,000 | 395,000 |
Change in fair value of loans held-for-sale | 6,000 | (376,000) |
Other | 48,000 | 4,000 |
Total Non-Interest Income | 2,144,000 | 986,000 |
Non-Interest Expense | ||
Salaries and employee benefits | 2,413,000 | 1,591,000 |
Occupancy | 433,000 | 322,000 |
Federal deposit insurance premiums | 57,000 | 62,000 |
Data processing related operations | 229,000 | 189,000 |
Professional fees | 191,000 | 132,000 |
Other expenses | 606,000 | 404,000 |
Total Non-Interest Expense | 3,929,000 | 2,700,000 |
Income before income taxes | 197,000 | 38,000 |
Income Tax Expense (Benefit) | 48,000 | (24,000) |
Net Income | $ 149,000 | $ 62,000 |
Net Income per share: | ||
Basic | $ 0.07 | $ 0.03 |
Diluted | $ 0.07 | $ 0.03 |
Unaudited Consolidated Statem_2
Unaudited Consolidated Statements of Comprehensive Income - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Statement Of Income And Comprehensive Income [Abstract] | |||
Net Income | $ 149,000 | $ 62,000 | |
Other comprehensive income, net of tax: | |||
Unrealized gain on available-for-sale securities (pre-tax $127 and $352, respectively) | 89,000 | 249,000 | |
Reclassification for gains included in income (pre-tax ($211) and $0, respectively) | [1] | 3,000 | |
Other comprehensive income | 89,000 | 246,000 | |
Comprehensive Income | $ 238,000 | $ 308,000 | |
[1] | Amounts are included in gain on sale of available-for-sale securities on the Consolidated Statements of Income as a separate element within non-interest income. Income tax expense is included in the Consolidated Statements of Income. |
Unaudited Consolidated Statem_3
Unaudited Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Statement Of Income And Comprehensive Income [Abstract] | ||
Unrealized gain on available-for-sale securities, pre-tax | $ 127 | $ 352 |
Reclassification for gains included in income, pre-tax | $ 0 | $ 4 |
Unaudited Consolidated Statem_4
Unaudited Consolidated Statements of Changes in Shareholders' Equity - USD ($) | Total | Common Stock | Treasury Stock | Additional Paid in Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Unearned ESOP Shares |
Beginning balance at Dec. 31, 2018 | $ 31,411,000 | $ 23,000 | $ 20,487,000 | $ 13,686,000 | $ (548,000) | $ (2,237,000) | |
Beginning balance, shares at Dec. 31, 2018 | 2,255,125 | ||||||
ESOP shares committed to be released | 31,000 | 2,000 | 29,000 | ||||
Stock option expense | 14,000 | 14,000 | |||||
Restricted stock expense | 45,000 | 45,000 | |||||
Net Income | 62,000 | 62,000 | |||||
Other comprehensive income | 246,000 | 246,000 | |||||
Restricted stock awards, shares | 4,000 | ||||||
Ending balance at Mar. 31, 2019 | 31,809,000 | $ 23,000 | 20,548,000 | 13,748,000 | (302,000) | (2,208,000) | |
Ending balance, shares at Mar. 31, 2019 | 2,259,125 | ||||||
Beginning balance at Dec. 31, 2019 | 33,599,000 | $ 23,000 | $ (3,000) | 20,740,000 | 14,973,000 | (18,000) | (2,116,000) |
Beginning balance, shares at Dec. 31, 2019 | 2,268,917 | ||||||
ESOP shares committed to be released | 35,000 | 5,000 | 30,000 | ||||
Treasury stock purchases | (145,000) | (145,000) | |||||
Treasury stock purchases, shares | (11,465) | ||||||
Stock option exercise | $ 24,000 | 24,000 | |||||
Exercise of stock options (in shares) | 1,600 | 1,600 | |||||
Stock option expense | $ 15,000 | 15,000 | |||||
Restricted stock expense | 47,000 | 47,000 | |||||
Net Income | 149,000 | 149,000 | |||||
Other comprehensive income | 89,000 | 89,000 | |||||
Ending balance at Mar. 31, 2020 | $ 33,813,000 | $ 23,000 | $ (148,000) | $ 20,831,000 | $ 15,122,000 | $ 71,000 | $ (2,086,000) |
Ending balance, shares at Mar. 31, 2020 | 2,259,052 |
Unaudited Consolidated Statem_5
Unaudited Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash Flows from Operating Activities | ||
Net income | $ 149,000 | $ 62,000 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation | 139,000 | 98,000 |
Amortization of net deferred loan costs | 121,000 | 57,000 |
Amortization of net securities premiums | 17,000 | 27,000 |
Amortization of operating lease right-of-use Assets | 132,000 | |
Gain on sale of available-for-sale securities, net | (4,000) | |
Gain from derivative instruments, net | (384,000) | (395,000) |
Provision for Loan Losses | 111,000 | 241,000 |
Deferred income taxes | 182,000 | 93,000 |
Accretion of deferred gain on sale-leaseback transaction | (3,000) | |
Earnings on bank owned life insurance | (38,000) | (39,000) |
Stock based compensation expense | 62,000 | 59,000 |
ESOP compensation expense | 35,000 | 31,000 |
Loans held for sale: | ||
Originations, net of prepayments | (77,226,000) | (17,106,000) |
Proceeds from sales | 79,369,000 | 28,474,000 |
Gain on sales | (1,629,000) | (890,000) |
Change in fair value of loans held for sale | (6,000) | 376,000 |
Changes in assets and liabilities which provided (used) cash: | ||
Accrued interest receivable | (145,000) | (53,000) |
Other assets | (163,000) | (156,000) |
Other liabilities | 259,000 | (298,000) |
Net cash provided by operating activities | 985,000 | 10,574,000 |
Cash Flows from Investing Activities | ||
Net (increase) decrease in loans receivable | 2,096,000 | (4,039,000) |
Activity in available-for-sale securities: | ||
Proceeds from sales | 0 | 1,956,000 |
Maturities and repayments | 2,395,000 | 1,974,000 |
Purchases | (4,329,000) | |
Activity in held-to-maturity securities: | ||
Maturities and repayments | 7,000 | |
Purchases of restricted investment in bank stock | (275,000) | (38,000) |
Redemption of restricted investment in bank stock | 76,000 | 42,000 |
Purchases of premises and equipment | (153,000) | (227,000) |
Net cash used in investing activities | (190,000) | (325,000) |
Cash Flows from Financing Activities | ||
Net decrease in deposits | (5,582,000) | (14,332,000) |
Net decrease in advances from borrowers for taxes and insurance | (202,000) | (342,000) |
Net increase in securities sold under agreements to repurchase | 315,000 | |
Net increase in short-term borrowing from Federal Home Loan Bank | 5,000,000 | |
Proceeds from stock option exercise | 24,000 | |
Purchase of treasury stock | (145,000) | |
Net cash used in financing activities | (905,000) | (14,359,000) |
Decrease in Cash and Cash Equivalents | (110,000) | (4,110,000) |
Cash and Cash Equivalents, beginning of year | 20,625,000 | 16,992,000 |
Cash and Cash Equivalents, end of year | 20,515,000 | 12,882,000 |
Supplementary Disclosure of Cash Flow Information | ||
Cash paid during the year of interest | 1,052,000 | $ 840,000 |
Cash paid during the year for income taxes | $ 19,000 |
Organization, Basis of Presenta
Organization, Basis of Presentation and Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization, Basis of Presentation and Recent Accounting Pronouncements | 1. ORGANIZATION, BASIS OF PRESENTATION and RECENT ACCOUNTING PRONOUNCEMENTS Organization HV Bancorp, Inc., a Pennsylvania Corporation (the “Company”) is the holding company of Huntingdon Valley Bank (the “Bank”) and was formed in connection with the conversion of the Bank from the mutual to the stock form of organization. On January 11, 2017, the mutual to stock conversion of the Bank was completed and the Company became the parent holding company for the Bank. Shares of the Company began trading on the Nasdaq Capital Market on January 12, 2017. The Company is subject to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve Bank”). The Bank is a stock savings bank organized under the laws of the Commonwealth of Pennsylvania and is subject to comprehensive regulation and examination by the Federal Deposit Insurance Corporation (“FDIC”) and the Pennsylvania Department of Banking and Securities (“PADOB”). The Bank was organized in 1871, and currently provides residential and commercial loans to its general service area (Montgomery, Bucks and Philadelphia Counties of Pennsylvania and New Castle County, Delaware) as well as offering a wide variety of savings, checking and certificate of deposit accounts to its retail and business customers. Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim information and with the instructions to the Quarterly Report on Form 10-Q, as applicable to a smaller reporting company. Accordingly, they do not include all the information and footnotes required by US GAAP for complete financial statements. The financial statements are unaudited; but in the opinion of management include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation thereof. The balances as of December 31, 2019 have been derived from the audited consolidated financial statements. These financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto contained in the Annual Report on Form 10-KT filed by the Company with the U.S. Securities and Exchange Commission on March 27, 2020 The Company has evaluated subsequent events through the date of issuance of the financial statements included herein. Significant Event T he COVID-19 pandemic has adversely affected economic activity globally, nationally and locally. It has caused substantial disruption in international and U.S. economies, markets, and employment. In response to the COVID-19 national emergency, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was passed by Congress and signed into law by President Trump on March 27, 2020. The CARES Act provides an estimated $2.2 trillion of economy-wide financial stimulus to combat the pandemic and stimulate the economy in the form of financial aid to individuals, businesses, nonprofits, states, and municipalities through loans, grants, tax changes, and other types of relief. Some of the applicable provisions of the Cares Act to the Company include, but are not limited to • Accounting for Loan Modifications – Under Section 4013 of the CARES Act, a financial institution may elect to temporarily suspend (1) the requirements under GAAP for certain loan modifications that would otherwise be categorized as a Troubled Debt Restructuring (“TDR”) and (2) does not need to determine impairment associated with the loan modifications. As of March 31, 2020, the Company entered into four loan modification agreement with an outstanding balance of $1.2 million. As of April 20, 2020, the Company entered into a total of 19 loan modification agreements with respect to $6.9 million of loans outstanding. • Paycheck Protection Program - The CARES Act authorized the Small Business Administration (“SBA”) to temporarily guarantee loans under a new 7(a) loan program called the Paycheck Protection Program (“PPP”). In early April 2020, the Company began accepting and processing applications for loans under the Paycheck Protection Program. As of April 30, 2020, the Company had received over 330 applications from new and existing customers and disbursed approximately $48 million in funds with an estimated processing fee income of approximately $1.5 million. • Mortgage Forbearance - Under Section 4022 of the CARES Act, through the earlier of December 31, 2020, or the 60th day after the termination date of the COVID-19 national emergency, a borrower with a federally backed mortgage loan that is experiencing a financial hardship due to COVID-19 may request a forbearance, regardless of delinquency status, for up to 180 days, which must be extended for an additional 180 days at the borrower’s request. During this period, no fees, penalties, or interest beyond those scheduled or calculated as if the borrower had made all contractual payments on time and in full will accrue. A multifamily borrower with a federally backed multifamily mortgage loan that was current as of February 1, 2020, and is experiencing financial hardship due to COVID-19 may request forbearance on the loan for up to 30 days, with up to two additional 30-day periods at the borrower’s request. As of March 31, 2020, we received 17 deferral agreements with respect to $10.9 million of loans outstanding. As of April 30, 2020 we received a total of 54 deferral agreements with respect to $20.3 million of loans outstanding. For further discussion, see COVID-19 update section of Item 2-Management’s Discussion and Analysis of Financial Condition and Results of Operations. Principles of Consolidation The unaudited interim consolidated financial statements include accounts of the Company and its wholly-owned subsidiary, the Bank. All significant intercompany transactions and balances have been eliminated in consolidation. Use of Estimates in the Preparation of Financial Statements In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the Statement of Financial Condition and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the determination of the allowance for loan losses, other-than-temporary impairments of securities (“OTTI”), interest rate lock commitments (“IRLCs”), mandatory sales commitments, the valuation of mortgage loans held-for-sale and the valuation of deferred tax assets. Recent Accounting Pronouncements The Company qualifies under the Jumpstart Our Business Startups Act (the “JOBS Act”) as an emerging growth company. As an emerging growth company, the Company has elected to use the extended transition period to delay adoption of new or revised accounting pronouncements until such pronouncements are made applicable to private companies. In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires credit losses on most financial assets measured at amortized cost and certain other instruments to be measured using an expected credit loss model (referred to as the current expected credit loss (CECL) model). Under this model, entities will estimate credit losses over the entire contractual term of the instrument (considering estimated prepayments, but not expected extensions or modifications unless reasonable expectation of a troubled debt restructuring exists) from the date of initial recognition of that instrument. The ASU also replaces the current accounting model for purchased credit impaired loans and debt securities. The allowance for credit losses for purchased financial assets with a more-than insignificant amount of credit deterioration since origination (“PCD assets”), should be determined in a similar manner to other financial assets measured on an amortized cost basis. However, upon initial recognition, the allowance for credit losses is added to the purchase price (“gross up approach”) to determine the initial amortized cost basis. The subsequent accounting for PCD financial assets is the same expected loss model described above. Further, the ASU made certain targeted amendments to the existing impairment model for available-for-sale (“AFS”) debt securities. For an AFS debt security for which there is neither the intent nor a more-likely-than-not requirement to sell, an entity will record credit losses as an allowance rather than a write-down of the amortized cost basis. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019, and early adoption is permitted for annual and interim periods beginning after December 15, 2018. With certain exceptions, transition to the new requirements will be through a cumulative effect adjustment to opening retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments ‒ Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) We expect to recognize a one-time cumulative effect adjustment to the allowance for loan losses as of the beginning of the first reporting period in which the new standard is effective, but cannot yet determine the magnitude of any such one-time adjustment or the overall impact of the new guidance on the consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, Topic 326, Financial Instruments – Credit Losses Topic 815, Derivatives and Hedging Topic 825, Financial Instruments Financial Instruments ‒ Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) The Company qualifies as a smaller reporting company and does not expect to early adopt these ASUs. Adoption of New Accounting Standards In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes the Disclosure Requirements for Fair Value Measurements the Company’s consolidated statement of financial condition. |
Investment Securities
Investment Securities | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Investment Securities | 2. INVESTMENT SECURITIES Investment securities available-for-sale was comprised of the following: March 31, 2020 Gross Gross Amortized Unrealized Unrealized (Dollars in thousands) Cost Gains Losses Fair Value U.S. Governmental securities $ 420 $ 2 $ — $ 422 Corporate notes 9,286 143 (185 ) 9,244 Collateralized mortgage obligations - agency residential 6,168 69 (50 ) 6,187 Mortgage-backed securities - agency residential 3,864 99 — 3,963 Municipal securities 2,113 5 — 2,118 Bank CDs 1,248 18 — 1,266 $ 23,099 $ 336 $ (235 ) $ 23,200 Investment securities available-for-sale was comprised of the following: December 31, 2019 Gross Gross Amortized Unrealized Unrealized (Dollars in thousands) Cost Gains Losses Fair Value U.S. Governmental securities $ 438 $ — $ (2 ) $ 436 Corporate notes 5,500 75 (6 ) 5,569 Collateralized mortgage obligations - agency residential 6,562 4 (102 ) 6,464 Mortgage-backed securities - agency residential 4,070 12 (19 ) 4,063 Municipal securities 2,114 3 — 2,117 Bank CDs 2,498 9 — 2,507 $ 21,182 $ 103 $ (129 ) $ 21,156 The scheduled maturities of securities available-for-sale at March 31, 2020 March 31, 2020 Available-for-Sale Amortized (Dollars in thousands) Cost Fair Value Due in one year or less $ 1,875 $ 1,878 Due from one to five years 7,772 7,765 Due from after five to ten years 3,001 2,986 Due after ten years 10,451 10,571 $ 23,099 $ 23,200 Securities with a fair value of $7.2 million and $7.4 million at March 31, 2020 and December 31, 2019, respectively, were pledged to secure public deposits and for other purposes as required by law. There were no proceeds from the sale of available-for-sale securities for the three months ended March 31, 2020. There were no gross realized gains or losses on sales for the three months ended March 31, 2020. Proceeds from the sale of available-for-sale securities for the three months ended March 31, 2019 were $2.0 million. Gross realized gains on such sales were approximately $4,000 and gross realized losses were $0 for the three months ended March 31, 2019. The following tables summarize the unrealized loss positions of securities available-for-sale as of March 31, 2020 and December 31, 2019: March 31, 2020 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized (Dollars in thousands) Value Loss Value Loss Value Loss Available-for-sale: U.S. Governmental securities $ — $ — $ — $ — $ — $ — Corporate notes 1,479 (50 ) 2,365 (135 ) 3,844 (185 ) Collateralized mortgage obligations 960 (38 ) 1,392 (12 ) 2,352 (50 ) Mortgage-backed securities — — — — — — Municipal securities — — — — — — Bank CDs — — — — — — $ 2,439 $ (88 ) $ 3,757 $ (147 ) $ 6,196 $ (235 ) December 31, 2019 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized (Dollars in thousands) Value Loss Value Loss Value Loss Available-for-sale: U.S. Governmental securities $ — $ — $ 436 $ (2 ) $ 436 $ (2 ) Corporate notes — — 1,494 (6 ) 1,494 (6 ) Collateralized mortgage obligations 1,486 (10 ) 3,810 (92 ) 5,296 (102 ) Mortgage-backed securities 922 (7 ) 1,438 (12 ) 2,360 (19 ) Municipal securities — — — — — — Bank CDs — — 250 — 250 — $ 2,408 $ (17 ) $ 7,428 $ (112 ) $ 9,836 $ (129 ) At March 31, 2020 and December 31, 2019, the investment portfolio included two U.S. Government securities with total fair values of $422,000 and $436,000, respectively. There were no securities in an unrealized loss position as of March 31, 2020. As of December 31, 2019, there were two securities in an unrealized loss position. These securities are zero risk weighted for capital purposes and are guaranteed for repayment of principal and interest. As of March 31, 2020 and December 31, 2019, management found no evidence of other-than-temporary (“OTTI”) on any of the U.S. Governmental securities in an unrealized loss position held in the investment securities portfolio. The Company has the ability to hold to maturity and more likely than not, will not be required to sell the securities before a recovery of the cost has occurred. At March 31, 2020 and December 31, 2019, the investment portfolio included fifteen and nine corporate notes, respectively with total fair values of $9.2 million and $5.6 million at the end of each of period, respectively. Of these securities, seven and three were in an unrealized loss position as of March 31, 2020 and December 31, 2019, respectively. At the time of purchase and as of March 31, 2020 and December 31, 2019, these bonds in an unrealized loss position continue to maintain investment grade ratings. As of March 31, 2020 and December 31, 2019, management found no evidence of OTTI on any of the corporate notes held in the investment securities portfolio. The Company has the ability to hold to maturity and more likely than not, will not be required to sell the securities before a recovery of the cost has occurred. At March 31, 2020 and December 31, 2019, the investment portfolio included thirty collateralized mortgage obligations (“CMOs”) with total fair values of $6.2 million and $6.5 million, respectively. Of these securities, twelve and twenty-seven were in an unrealized loss position as of March 31, 2020 and December 31, 2019, respectively. The CMO portfolio is comprised of 100% agency (FHLMC, FNMA and GNMA) investment grade bonds. As of March 31, 2020 and December 31, 2019, management found no evidence of OTTI on any of the CMOs held in the investment securities portfolio. The Company has the ability to hold to maturity and more likely than not, will not be required to sell the securities before a recovery of the cost has occurred. At March 31, 2020 and December 31, 2019, the investment portfolio included thirteen mortgage backed securities (“MBS”) with a total fair value of $4.0 million and $4.1 million, respectively. There were no securities in an unrealized loss position as of March 31, 2020. As of December 31, 2019, seven securities were in an unrealized loss position. The MBS portfolio is comprised of 100% agency (FHLMC, FNMA and GNMA) investment grade bonds. As of March 31, 2020 and December 31, 2019, management found no evidence of OTTI on any of the MBS held in the investment securities portfolio. The Company has the ability to hold to maturity and more likely than not, will not be required to sell the securities before a recovery of the cost has occurred. At March 31, 2020 and December 31, 2019, the investment portfolio included five municipal securities with a total fair value of $2.1 million for both periods. Of these securities, zero were in an unrealized loss position as of March 31, 2020 and December 31, 2019, respectively. The Company’s municipal portfolio issuers are located in Pennsylvania and at the time of purchase, and as of March 31, 2020 and December 31, 2019, continue to maintain investment grade ratings. As of March 31, 2020 and December 31, 2019, management found no evidence of OTTI on any of the municipal securities held in the investment securities portfolio. The Company has the ability to hold to maturity and more likely than not, will not be required to sell the securities before a recovery of the cost has occurred. At March 31, 2020 and December 31, 2019, the investment portfolio included five and ten Bank Certificate of Deposits (“CDs”) with a total fair value of $1.3 million and $2.5 million, respectively. As of March 31, 2020, there were no securities in an unrealized loss position. As of December 31, 2019, one of these securities was in an unrealized loss position. The Bank CDs |
Equity Securities
Equity Securities | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Equity Securities | 3. EQUITY SECURITIES The Company maintains an equity security portfolio that consists of $500,000 at March 31, 2020 and December 31, 2019. As of March 31, 2020 and December 31, 2019, the Company determined that the equity investment did not have a readily determinable fair value measure and is carrying the equity investment at cost, less impairment, adjusted for changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table presents the carrying amount of the Company’s equity investment at March 31, 2020 and December 31, 2019: March 31, 2020 (dollars in thousands) Year-to-date Life-to-date Amortized cost $ 500 $ 500 Impairment — — Observable price changes — — Carrying value $ 500 $ 500 December 31, 2019 (dollars in thousands) Year-to-date Life-to-date Amortized cost $ 500 $ 500 Impairment — — Observable price changes — — Carrying value $ 500 $ 500 At March 31, 2020 and December 31, 2019, the Company performed a qualitative assessment considering impairment indictors to evaluate whether the investment was impaired and determined the investment was not impaired. |
Loans Receivable
Loans Receivable | 3 Months Ended |
Mar. 31, 2020 | |
Receivables [Abstract] | |
Loans Receivable | 4. LOANS RECEIVABLE Loans receivable were comprised of the following: March 31, December 31, (Dollars in thousands) 2020 2019 Residential: One-to-four family $ 187,657 $ 197,547 Home equity and HELOCs 4,106 4,383 Commercial: Commercial real estate 38,795 35,188 Commercial business 14,349 11,119 Construction 2,090 784 Consumer: Medical education 5,953 6,097 Other 4 8 252,954 255,126 Unearned discounts, origination and commitment fees and costs 1,299 1,343 Allowance for loan losses (1,549 ) (1,437 ) $ 252,704 $ 255,032 In November 2017, the Bank entered into a loan purchase agreement with a broker to purchase a portfolio of private education loans made to American citizens attending American Medical Association (“AMA”) approved medical schools in Caribbean Nations. The broker serves as a lender, holder, program designer and developer, administrator, and secondary market for the loan portfolios they generate. At March 31, 2020, the balance of the private education loans was $5.9 million. The private student loans were made following a proven credit criteria and were underwritten in accordance with the Bank’s policies. At March 31, 2020, there were eight loans with a balance of approximately $460,000 that are past due 90 days or more. Overdraft deposits are reclassified as other consumer and are included in the total loans on the statements of financial condition. Overdrafts were $4,000 and $8,000 at March 31, 2020 The following tables summarize the activity in the allowance for loan losses by loan class for the three months ended March 31, 2020 and 2019. Allowance for Loan Losses For the three months ended March 31, 2020 (Dollars in thousands) Beginning Balance Charge- offs Recoveries (Credit) Provisions Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairments Residential: One-to-four family $ 701 $ — $ — $ 59 $ 760 $ — $ 760 Home equity and HELOCs 44 — — (31 ) 13 — 13 Commercial: Commercial real estate 229 — — 40 269 — 269 Commercial business 122 — — 32 154 — 154 Construction 8 — — 14 22 — 22 Consumer: Medical education 333 — 1 (3 ) 331 — 331 Other — — — — — — $ 1,437 $ — $ 1 $ 111 $ 1,549 $ — $ 1,549 Allowance for Loan Losses For the three months ended March 31, 2019 (Dollars in thousands) Beginning Balance Charge- offs Recoveries (Credit) Provisions Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairments Residential: One-to-four family $ 722 $ — $ — $ 7 $ 729 $ — $ 729 Home equity and HELOCs 46 — — — 46 — 46 Commercial: Commercial real estate 59 — — 2 61 — 61 Commercial business 59 — — 7 66 13 53 Construction 13 — — 2 15 — 15 Consumer: Medical education 56 (141 ) — 223 138 — 138 Other 1 (1 ) — — — — — $ 956 $ (142 ) $ — $ 241 $ 1,055 $ 13 $ 1,042 The Company maintains a general allowance for loan losses based on evaluating known and inherent risks in the loan portfolio, including management’s continuing analysis of the factors underlying the quality of the loan portfolio. These factors include changes in the size and composition of the loan portfolio, actual loan loss experience, and current and anticipated economic conditions. The reserve is an estimate based upon factors and trends identified by management at the time the financial statements are prepared. Due to uncertainty of economic conditions from the COVID-19 pandemic, the Company increased the qualitative factors in the calculation of the allowance for loan losses. However, due to the uncertainty of the impact, the Company will continue to monitor and additional adjustments to the allowance for loan losses may be necessary. The following tables summarize information in regard to the recorded investment in loans receivable by loan class as of March 31, 2020 and December 31, 2019: March 31, 2020 Loans Receivable (Dollars in thousands) Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairment Residential One-to-four family $ 187,657 $ 1,539 $ 186,118 Home equity and HELOCs 4,106 279 3,827 Commercial Commercial real estate 38,795 313 38,482 Commercial business 14,349 114 14,235 Construction 2,090 — 2,090 Consumer: Medical education 5,953 — 5,953 Other 4 — 4 $ 252,954 $ 2,245 $ 250,709 December 31, 2019 Loans Receivable (Dollars in thousands) Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairment Residential One-to-four family $ 197,547 $ 1,566 $ 195,981 Home equity and HELOCs 4,383 308 4,075 Commercial Commercial real estate 35,188 317 34,871 Commercial business 11,119 120 10,999 Construction 784 — 784 Consumer: Medical education 6,097 — 6,097 Other 8 — 8 $ 255,126 $ 2,311 $ 252,815 The following table summarizes information about impaired loans by loan portfolio class as of March 31, 2020 and December 31, 2019 March 31, 2020 December 31, 2019 (Dollars in thousands) Recorded Investment Unpaid Principal Balance Related Allowance Recorded Investment Unpaid Principal Balance Related Allowance With no related allowance recorded Residential: One-to-four family $ 1,539 $ 1,692 $ — $ 1,566 $ 1,703 $ — Home equity and HELOCs 55 76 — 308 308 — Commercial: Commercial real estate 313 313 — 317 317 — Commercial business 114 114 — — — — Consumer: Medical education — — — — — — 2,021 2,195 — 2,191 2,328 — With an allowance recorded Residential: Home equity and HELOCs 224 227 1 — — — Commercial: Commercial business — — — 120 121 12 224 227 1 120 121 12 $ 2,245 $ 2,422 $ 1 $ 2,311 $ 2,449 $ 12 The following table presents additional information regarding the impaired loans for the three months ended March 31, 2020 and Three Months Ended March 31, 2020 2019 (Dollars in thousands) Average Record Investment Interest Income Recognized Average Record Investment Interest Income Recognized With no related allowance recorded Residential: One-to-four family $ 1,552 $ — $ 1,425 $ — Home equity and HELOCs 294 — 67 — Commercial: Commercial real estate 315 6 388 7 Commercial business 117 2 — — Consumer: Medical education — — 258 — 2,278 8 2,138 7 With an allowance recorded Commercial business — — 139 2 — — 139 2 $ 2,278 $ 8 $ 2,277 $ 9 If these loans were performing under the original contractual rate, interest income on such loans would have increased approximately $24,000 and $22,000 for the three months ended March 31, 2020 and 2019, respectively. The following table presents nonaccrual loans by classes of the loan portfolio as of March 31, 2020 and December 31, 2019 March 31, December 31, (Dollars in thousands) 2020 2019 Residential: One-to-four family $ 1,656 $ 1,686 Home equity and HELOCs 279 308 Commercial: Commercial real estate — — Commercial business — — Construction — — Consumer: Medical education 1,849 1,710 Other — — $ 3,784 $ 3,704 Credit quality risk ratings include regulatory classifications of Special Mention, Substandard, Doubtful and Loss. Loans classified as Special Mention have potential weaknesses that deserve management’s close attention. If uncorrected, the potential weaknesses may result in deterioration of prospects for repayment. Loans classified substandard have a well-defined weakness or weaknesses that jeopardize the liquidation of the debt. They include loans that are inadequately protected by the current net worth and paying capacity of the obligor or of the collateral pledged, if any. Loans classified doubtful have all the weaknesses inherent in loans classified substandard with the added characteristic that collection or liquidation in full, on the basis of current conditions and facts, is highly improbable. Loans classified as a loss are considered uncollectible and are charged to the allowance for loan losses. Loans not classified are rated pass. Included in the non-performing medical education loans are non-accrual loans that have been brought current through a status change to deferred status. The deferred status generally means the student is in medical residency. Generally, the loan may be restored to accrual status when the obligation is in accordance with the contractual terms for a reasonable period of time, generally six months. The following tables summarize the aggregate Pass and criticized categories of Special Mention, Substandard and Doubtful within the Company’s internal risk rating system as of March 31, 2020 and December 31, 2019: March 31, 2020 Special (Dollars in thousands) Pass Mention Substandard Doubtful Total Residential: One-to-four family $ 186,001 $ — $ 1,656 $ — $ 187,657 Home equity and HELOCs 3,827 — 279 — 4,106 Commercial: Commercial real estate 38,281 201 313 — 38,795 Commercial business 14,170 — 179 — 14,349 Construction 2,090 — — — 2,090 Consumer: Medical education 4,104 — 1,849 — 5,953 Other 4 — — — 4 $ 248,477 $ 201 $ 4,276 $ — $ 252,954 December 31, 2019 Special (Dollars in thousands) Pass Mention Substandard Doubtful Total Residential: One-to-four family $ 195,861 $ — $ 1,686 $ — $ 197,547 Home equity and HELOCs 4,075 — 308 — 4,383 Commercial: Commercial real estate 34,667 204 317 — 35,188 Commercial business 10,924 — 195 — 11,119 Construction 784 — — — 784 Consumer: Medical education 4,387 — 1,710 — 6,097 Other 8 — — — 8 $ 250,706 $ 204 $ 4,216 $ — $ 255,126 The following tables present the segments of the loan portfolio summarized by aging categories as of March 31, 2020 and December 31, 2019: March 31, 2020 (Dollars in thousands) 30-59 Days Past Due 60-89 Days Past Due Greater than 90 Days Total Past Due Current Total Loans Receivable Loans Receivable >90 Days and Accruing Residential: One-to-four family $ 475 $ 656 $ 299 $ 1,430 $ 186,227 $ 187,657 $ — Home equity and HELOCs — 71 — 71 4,035 4,106 — Commercial: Commercial real estate — — — — 38,795 38,795 — Commercial business — — — — 14,349 14,349 — Construction — — — — 2,090 2,090 — Consumer: Medical education 358 243 460 1,061 4,892 5,953 — Other — — — — 4 4 — $ 833 $ 970 $ 759 $ 2,562 $ 250,392 $ 252,954 $ — December 31, 2019 (Dollars in thousands) 30-59 Days Past Due 60-89 Days Past Due Greater than 90 Days Total Past Due Current Total Loans Receivable Loans Receivable >90 Days and Accruing Residential: One-to-four family $ 365 $ 94 $ 359 $ 818 $ 196,729 $ 197,547 $ — Home equity and HELOCs — — — — 4,383 4,383 — Commercial: Commercial real estate — — — — 35,188 35,188 — Commercial business — — — — 11,119 11,119 — Construction — — — — 784 784 — Consumer: Medical education 103 53 709 865 5,232 6,097 — Other — — — — 8 8 — $ 468 $ 147 $ 1,068 $ 1,683 $ 253,443 $ 255,126 $ — The Company may grant a concession or modification for economic or legal reasons related to a borrower's financial condition that it would not otherwise consider resulting in a modified loan that is then identified as a troubled debt restructuring (“TDR”). The Company may modify loans through rate reductions, extensions of maturity, interest only payments, or payment modifications to better match the timing of cash flows due under the modified terms with the cash flows from the borrowers' operations. Loan modifications are intended to minimize the economic loss and to avoid foreclosure or repossession of the collateral. TDRs are considered impaired loans for purposes of calculating the Company's allowance for loan losses. TDRs are restored to accrual status when the obligation is brought current, has performed in accordance with the modified contractual terms for a reasonable period of time, generally six months, and the ultimate collectability of the total contractual principal and interest is no longer in doubt. The Company may identify loans for potential restructure primarily through direct communication with the borrower and evaluation of the borrower's financial statements, revenue projections, tax returns, and credit reports. Even if the borrower is not presently in default, management will consider the likelihood that cash flow shortages, adverse economic conditions and negative trends may result in a payment default in the near future. The Company began offering short-term loan modifications to provide assistance to borrowers during the COVID-19 pandemic. The CARES Act along with a joint agency statement issued by federal and state banking agencies, provides that short-term modifications made on a good faith basis in response to COVID-19 who were current at the time the modification program is implemented As of March 31, 2020 and December 31, 2019, the Company had two loans identified as TDRs totaling $251,000 and $259,000, respectively. At March 31, 2020 and December 31, 2019, the two TDRs were performing in compliance with their restructured terms and on accrual status. There were no modifications to loans classified as TDRs during the three months ended March 31, 2020 and 2019. No additional loan commitments were outstanding to these borrowers at March 31, 2020 and December 31, 2019. At March 31, 2020, there was no specific reserves related to the TDRs. At December 31, 2019, there was a specific reserve of $12,000 related to one TDR. The following table details the Company’s TDRs that are on accrual status and non-accrual status at March 31, 2020: As of March 31, 2020 Number Accrual Non-Accrual (Dollars in thousands) Of Loans Status Status Total TDRs Commercial real estate 1 $ 137 $ — $ 137 Commercial business 1 114 — 114 Total 2 $ 251 $ — $ 251 The following table details the Company’s TDRs that are on accrual status and non-accrual status at December 31, 2019: As of December 31, 2019 Number Accrual Non-Accrual (Dollars in thousands) Of Loans Status Status Total TDRs Commercial real estate 1 $ 139 $ — $ 139 Commercial business 1 120 — 120 Total 2 $ 259 $ — $ 259 The carrying amount of residential mortgage loans in the process of foreclosure was $394,000 and $403,000 at March 31, 2020 and December 31, 2019, respectively. |
Derivatives and Risk Management
Derivatives and Risk Management Activities | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Derivatives and Risk Management Activities | 5. DERIVATIVES AND RISK MANAGEMENT ACTIVITIES The Company did not have any derivative instruments designated as hedging instruments or subject to master netting and collateral agreements as of March 31, 2020 and December 31, 2019. The following tables summarize the amounts recorded in the Company’s consolidated statements of financial condition for derivatives not designated as hedging instruments as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 Asset Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Mortgage banking derivatives $ 1,939 $ 102,349 Forward loan sales commitments Mortgage banking derivatives 297 7,266 To Be Announced securities ("TBAs") Mortgage banking derivatives — — Liability Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Other liabilities $ 32 $ 4,815 Forward loan sales commitments Other liabilities 87 8,863 TBA securities Other liabilities 655 26,000 December 31, 2019 Asset Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Mortgage banking derivatives $ 810 $ 25,059 Forward loan sales commitments Mortgage banking derivatives 389 11,036 TBA securities Mortgage banking derivatives 5 3,500 Liability Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Other liabilities $ 25 $ 3,820 Forward loan sales commitments Other liabilities 45 10,595 TBA securities Other liabilities 56 24,500 The following table summarizes the amounts recorded in the Company’s consolidated statements of income for derivative instruments not designated as hedging instruments for the three months ended March 31, 2020 and 2019 (in thousands): Gain Consolidated Statements of Income Three Months Ended Presentation March 31, 2020 March 31, 2019 Interest rate lock commitments Gain from derivative instruments $ 1,122 $ 453 Forward loan sales commitments Loss from derivative instruments (134 ) (14 ) TBA securities Loss from derivative instruments (604 ) (44 ) Total gain from derivative instruments $ 384 $ 395 |
Fair Value Presentation
Fair Value Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Presentation | 6. The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in many instances, there are no quoted market prices for the Company’s various financial instruments. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the instrument. Fair value guidance provides a consistent definition of fair value, which focuses on exit price in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment. The fair value is determined at a reasonable point within the range that is most representative of fair value under current market conditions. Management uses its best judgment in estimating the fair value of the Company’s financial instruments; however, there are inherent weaknesses in any estimation technique. Therefore, for substantially all financial instruments, the fair value estimates herein are not necessarily indicative of the amounts the Company could have realized in sales transaction on the dates indicated. The estimated fair value amounts have been measured as of their respective year-ends, and have not been reevaluated or updated for purposes of these financial statements subsequent to those respective dates. As such, the estimated fair values of these financial instruments subsequent to the respective reporting dates may be different than the amounts reported at each year-end. In accordance with this guidance, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. Level 1 – Valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2 – Valuation is based on inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly. The valuation may be based on quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which determination of fair value requires significant management judgment or estimation. The following tables provide the fair value for assets required to be measured and reported at fair value on a recurring basis as of March 31, 2020 and December 31, 2019: March 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Investment securities available-for-sale: U.S. Governmental securities $ — $ 422 $ — $ 422 Corporate notes — 6,211 3,033 9,244 Collateralized mortgage obligations - agency residential — 6,187 — 6,187 Mortgage-backed securities - agency residential — 3,963 — 3,963 Municipal securities — 2,118 — 2,118 Bank CDs — 1,266 — 1,266 Loans held for sale — 37,368 — 37,368 Interest rate lock commitments — — 1,939 1,939 Forward loan sales commitments — 297 — 297 TBA securities — — — — $ — $ 57,832 $ 4,972 $ 62,804 December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Investment securities available-for-sale: U.S. Governmental securities $ — $ 436 $ — $ 436 Corporate notes — 2,510 3,059 5,569 Collateralized mortgage obligations - agency residential — 6,464 — 6,464 Mortgage-backed securities - agency residential — 4,063 — 4,063 Municipal securities — 2,117 — 2,117 Bank CDs — 2,507 — 2,507 Loans held for sale — 37,876 — 37,876 Interest rate lock commitments — — 810 810 Forward loan sales commitments — 389 — 389 TBA securities — 5 — 5 $ — $ 56,367 $ 3,869 $ 60,236 The following tables provide the fair value for liabilities required to be measured and reported at fair value on a recurring basis as of March 31, 2020 and December 31, 2019. March 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Interest rate lock commitments $ — $ — $ 32 $ 32 Forward loan sales commitments — 87 — 87 TBA securities — 655 — 655 $ — $ 742 $ 32 $ 774 December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Interest rate lock commitments $ — $ — $ 25 $ 25 Forward loan sales commitments — 45 — 45 TBA securities — 56 — 56 $ — $ 101 $ 25 $ 126 The following tables represent the change in the assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three ended March 31, 2020 and 2019: (Dollars in thousands) Corporate notes IRLC- Asset IRLC- Liability Beginning Balance: January 1, 2020 $ 3,059 $ 810 $ (25 ) Total unrealized losses: Included in other comprehensive income (26 ) — — Total gains or (losses) included in earnings and held at reporting date — 1,129 (7 ) Transfers in and/or out of Level 3 — — — Ending Balance: March 31, 2020 $ 3,033 $ 1,939 $ (32 ) Change in unrealized gains or (losses) for the period included in earnings (or changes in net assets) for assets held as of March 31, 2020 — 1,129 (7 ) Change in unrealized gains for the period included other comprehensive income for assets held as of March 31, 2020 $ 26 $ — $ — (Dollars in thousands) Corporate notes IRLC- Asset IRLC- Liability Beginning Balance: January 1, 2019 $ 494 $ 218 $ (18 ) Total unrealized losses: Included in other comprehensive income (2 ) — — Total gains or (losses) included in earnings and held at reporting date — 462 (9 ) Transfers in and/or out of Level 3 — — — Ending Balance: March 31, 2019 $ 492 $ 680 $ (27 ) At March 31, 2020, the Company has classified $3.0 million of Corporate notes as Level 3. The fair value of $1.0 million of Corporate notes includes an adjustable rate corporate security and sub-debt bond. The Company’s methodology for valuing these Corporate notes is to obtain market quotes through a third-party pricing model. The weighted average of the market quotes applied range from $92.37 to $104.66. In addition, classified as Level 3 are two sub-debt bonds with a fair value of $2.0 million. The Company’s methodology to value the two sub-debt bonds is to obtain from a broker/investment firm market values of similar sub-debt bonds issuances over the past twelve months. Since the Corporate notes are not widely traded, the Company considered the inputs as unobservable At March 31, 2020, the Company has classified $1.9 million of net derivative assets and liabilities related to IRLC as Level 3. The fair value of IRLCs is based on prices obtained for loans with similar characteristics from third parties, adjusted by the pull-through rate, which represents the Company’s best estimate of the probability that a committed loan will fund. The weighted average pull-through rates applied ranging from 25% to 98%. Significant unobservable inputs for assets and liabilities measured at fair value on a recurring basis at March 31, 2020: Quantitative Information about Level 3 Fair Value Measurements at March 31, 2020 (Dollars in thousands) Fair Value Valuation Technique Significant Unobservable Input Range Weighted Average Measured at Fair Value on a Recurring Basis: Corporate notes $ 1,033 Pricing model Market quotes $92.37-$104.66 $ 101.24 $ 2,000 Market comparable securities Market quotes $ 102.00 $ 102.00 Net derivative asset and liability: IRLC $ 1,939 Discounted cash flows Pull-through rates 25%-98% 77% There were no assets measured at fair value on a nonrecurring basis at March 31, 2020 and December 31, 2019. The following table provides the carrying amount for each class of assets and liabilities and the fair value for certain financial instruments that are not required to be measured or reported at fair value on the Consolidated Statements of Financial Condition as of March 31, 2020 and December 31, 2019: Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable March 31, 2020 Carrying Estimated Assets Inputs Inputs (Dollars in thousands) Amount Fair Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 20,515 $ 20,515 $ 20,515 $ — $ — Equity securities 500 500 — — 500 Loans receivable, net (1) 252,704 260,389 — — 260,389 Bank-owned life insurance 6,293 6,293 6,293 — — Restricted investment in bank stock 1,751 1,751 1,751 — — Accrued interest receivable 1,112 1,112 1,112 — — Liabilities: Deposits $ 278,185 $ 278,599 $ 216,372 $ 62,227 $ — Advances from the FHLB 32,000 32,692 5,000 27,692 — Advances from borrowers for taxes and insurance 1,936 1,936 1,936 — — Accrued interest payable 186 186 186 — — Off-balance sheet: Commitment to extend credit $ — $ — $ — $ — $ — (1) In accordance with the prospective adoption of ASU No. 2016-01, the fair value of the loans as of September 30, 2019 and June 30, 2019 were measured using an exit price notion. Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable December 31, 2019 Carrying Estimated Assets Inputs Inputs (Dollars in thousands) Amount Fair Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 20,625 $ 20,625 $ 20,625 $ — $ — Equity securities 500 500 — — 500 Loans receivable, net (1) 255,032 254,884 — — 254,884 Bank-owned life insurance 6,255 6,255 6,255 — — Restricted investment in bank stock 1,552 1,552 1,552 — — Accrued interest receivable 967 967 967 — — Liabilities: Deposits $ 283,767 $ 284,055 $ 215,471 $ 68,584 $ — Advances from the FHLB 27,000 27,333 — 27,333 — Advances from borrowers for taxes and insurance 2,138 2,138 2,138 — — Accrued interest payable 305 305 305 — — Off-balance sheet: Commitment to extend credit $ — $ — $ — $ — $ — |
Changes in and Reclassification
Changes in and Reclassifications out of Accumulated Other Comprehensive Gain (Loss) | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Changes in and Reclassifications out of Accumulated Other Comprehensive Income (Loss) | 7. CHANGES IN AND RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The following tables present the changes in the balances of each component of accumulated other comprehensive income (loss) (“AOCI”) for the three months ended March 31, 2020 and March 31, 2019 Net unrealized holding gains on available-for-sales securities (1) For the three months ended (Dollars in thousands) March 31, 2020 March 31, 2019 Balance at beginning period $ (18 ) $ (548 ) Unrealized holding gain on available-for-sale securities before reclassification 89 249 Amount reclassified for investment securities gains included in net income — (3 ) Net current-period other comprehensive income 89 246 Balance at ending period $ 71 $ (302 ) (1) All amounts are net of tax. Related tax expense or benefit is calculated using an income tax rate of approximately 29.5% and 28.2% for the three months ended March 31, 2020 and 2019, respectively. The following table present reclassifications out of AOCI by component for the three months ended March 31, 2020 and March 31, 2019. For the three months ended March 31, 2020 For the three months ended March 31, 2019 (Dollars in thousands) Amount reclassified from accumulated other comprehensive income (loss) (2) Amount reclassified from accumulated other comprehensive income (loss) (2) Affected line item in the consolidated statements of income Net realized gain on available-for securities (1) $ — $ 4 Gain on sale of available-for-sale securities, net Tax Effect — (1) Income tax expense $ — $ 3 (1) For additional details related to unrealized gains on investment securities and related amounts reclassified from accumulated other comprehensive loss, See Note 2, “Investment securities.” (2) Amounts in parentheses indicate debits. |
Earnings per Share
Earnings per Share | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings per Share | 8. EARNINGS PER SHARE Earnings per share ("EPS") consist of two separate components: basic EPS and diluted EPS. Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for each period presented. The diluted EPS calculation reflects the EPS if all outstanding instruments convertible to common stock were exercised. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect. At there were 216,400 stock options outstanding of which 30,080 of the stock options were vested and exercisable at 87,000 restricted stock shares outstanding of which 12,320 restricted stock shares were vested and exercisable at . The 216,400 stock options outstanding and 65,981 restricted stock shares outstanding were not included in the computation of diluted net income per share for the three months ended as their effect would have been anti-dilutive The calculation of basic and diluted EPS for the three For the Three Months Ended March 31 2020 2019 Net income $ 149,000 $ 62,000 Weighted average number of shares issued 2,270,180 2,261,258 Less weighted average number of treasury shares (2,487 ) — Less weighted average number of unearned ESOP shares (146,954 ) (155,682 ) Less weighted average number of unvested restricted stock awards (67,050 ) (75,207 ) Basic weighted average shares outstanding 2,053,689 2,030,369 Add dilutive effect of stock options 75 — Add dilutive effect of restricted stock awards — — Diluted weighted average shares outstanding 2,053,764 2,030,369 Net income per share: Basic $ 0.07 $ 0.03 Diluted $ 0.07 $ 0.03 |
Employee Benefits
Employee Benefits | 3 Months Ended |
Mar. 31, 2020 | |
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract] | |
Employee Benefits | 9. EMPLOYEE BENFITS Equity Incentive Plan The Company’s shareholders approved the HV Bancorp, Inc. 2018 Equity Incentive Plan (the “2018 Equity Incentive Plan”) of authorized but unissued common stock of the Company was reserved for future grants of incentive and non-qualified stock options, restricted stock awards and restricted stock units under the 2018 Equity Incentive Plan. Of the 305,497 authorized shares, the maximum number of shares of the Company’s common stock that may be issued under the 2018 Equity Incentive Plan pursuant to the exercise of stock options is 218,212 shares, and the maximum number of shares of the Company’s common stock that may be issued as restricted stock awards or restricted stock units is 87,285 shares. The product of the number of shares granted and the grant date market price of the Company’s common stock determine the fair value of restricted stock under the Company’s 2018 Equity Incentive plan. Management recognizes compensation expense for the fair value of restricted stock on a straight-line basis over the requisite service period for the entire award. As of March 31, 2020, there were 497 shares available for future awards under this plan, which includes 212 shares available for incentive and non-qualified stock options and 285 shares available for restricted stock awards. The restricted shares and stock options vest over a seven year period. Stock option expense was $15,000 and $14,000 for the three months ended March 31, 2020 and March 31, 2019, respectively. At March 31, 2020, t A summary of the Company’s stock option activity and related information for the three months ended March 31, 2020 and March 31, 2019 was as follows: March 31, 2020 March 31, 2019 Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Average Intrinsic Value Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Average Intrinsic Value Outstanding, Jan 1 218,000 $ 14.92 8.6 $ 452,400 188,000 $ 14.80 9.4 $ 33,840 Granted — — — — 10,000 15.28 9.9 — Exercised (1,600 ) 14.82 — — — — — — Forfeited — — — — — — — — Outstanding, March 31 216,400 $ 14.93 8.4 $ — 198,000 $ 14.82 9.6 $ 253,440 Exercisable, March 31 30,080 $ 14.83 8.3 $ — — $ — — $ — Restricted stock expense for the three months ended March 31, 2020 and March 31, 2019 was $47,000 and $45,000, respectively. At March 31, 2020, the expected future compensation expense relating to non-vested restricted stock outstanding was $984,000. A summary of the Company’s restricted stock activity and related information for the three months ended March 31, 2020 and 2019 was as follows: March 31, 2020 March 31, 2019 Number of Shares Weighted- Average Grant Date Fair Value Number of Shares Weighted- Average Grant Date Fair Value Non-vested, Jan 1 75,320 $ 14.97 73,000 $ 14.80 Vested (640 ) 15.21 — — Granted — — 4,000 15.21 Forfeited — — — — Non-vested at March 31 74,680 $ 14.97 77,000 $ 14.82 |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 10. RELATED PARTY TRANSACTIONS In November 2017, the Company engaged a third party to provide services for certain customers with large deposit balances, by offering both a competitive rate of return and FDIC insurance. Related party balances in this program totaled $11.9 million at March 31, 2020 for which the Company received fees for customer services totaling approximately $2,000 and $5,000 in the three months ended March 31, 2020 and March 31, 2019, respectively. In January 2018, the Company entered into a business consulting agreement with one of our directors to provide deposit sales training, grow deposit market share and identify deposit opportunities. This agreement terminated on December 31, 2019. The Company has paid $15,000 in consulting fees to the director for three months ended March 31, 2019. |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Mar. 31, 2020 | |
Revenue From Contract With Customer [Abstract] | |
Revenue Recognition | 11. REVENUE RECOGNITION On July 1, 2018, the Company adopted ASU No. 2014-09 “Revenue from Contracts with Customers” (Topic 606) and all subsequent ASUs that modified Topic 606. The following is a discussion of key revenues of fees for customer services that are within the scope of the revenue guidance: • Fee income – Fee income primarily consists of a fee received for placing customer deposits in a deposit placement network such that amounts are under the standard FDIC insurance maximum of $250,000 making the deposits eligible for FDIC insurance. The Company acts as an intermediary between the customer and the deposit placement network. The Company’s performance obligation is generally satisfied upon placement of the customer’s deposit in deposit placement network. • Insufficient fund fees and other service charges – Revenue from service charges on deposit accounts is earned through cash management, wire transfer, and other deposit-related services; as well as overdraft, non-sufficient funds, account management and other deposit-related fees. Revenue is recognized for these services either over time, corresponding with deposit accounts’ monthly cycle, or at a point in time for transactional related services and fees. These revenues are included in insufficient funds fees and other service charges in the table below . • ATM interchange and fee income – ATM fees are primarily generated when a Company cardholder uses a non-Company ATM or a non-Company cardholder used a Company’s ATM. The Company’s performance obligation for ATM fee income are largely satisfied, and related revenue recognized, when the services are rendered or upon completion. The following table presents noninterest income for the three months ended March 31, 2020 and March 31, 2019: Three Months Ended March 31, (Dollars in thousands) 2020 2019 Non-Interest Income In-scope of Topic 606: Fee income $ 3 $ 5 Insufficient fund fees 17 12 Other service charges 17 11 ATM interchange fee income 2 2 Total Non-Interest Income (in-scope of Topic 606) $ 39 $ 30 Out-of-scope of Topic 606: Increase in cash surrender value of bank-owned life insurance $ 38 $ 39 Gain on sale of loans, net 1,629 890 Gain on sale of available-for-sale securities — 4 Gain from derivative instruments 384 395 Change in fair value for loans held-for-sale 6 (376 ) Other 48 4 Total Non-Interest Income (out-scope of Topic 606) 2,105 956 Total Non-Interest Income (in-scope of Topic 606) 39 30 Total Noninterest Income $ 2,144 $ 986 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Leases | 12. Leases On July 1, 2019, the Company adopted ASU No. 2016-02 “Leases” (Topic 842) The majority of the Company’s leases are comprised of operating leases for real estate property for branches and office spaces with terms extending through 2036. The operating lease agreements are recognized on the consolidated statements of financial condition as a right-of-use (“ROU”) asset and a corresponding lease liability. The Company elected not to include short-term leases with initial terms of twelve months or less on the consolidated statements of financial condition. The following table represents the classification of the Company’s ROU assets and lease liabilities in the consolidated statements of financial condition: March 31, 2020 December 31, 2019 Lease Right-of-Use Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets $ 6,187 $ 5,979 Total Lease Right-of-Use Assets $ 6,187 $ 5,979 March 31, 2020 December 31, 2019 Lease Liabilities Classification Operating lease liabilities Operating lease liabilities $ 6,296 $ 6,023 Total Lease Liabilities $ 6,296 $ 6,023 The Company’s lease agreements frequently include one or more options to renew at the Company’s discretion. If at the beginning of the lease, the Company is reasonably certain that the renewal option will be exercised, the Company will include the extended term in the calculation of the ROU asset and lease liability. For the discount rate, Topic 842 requires the use of the rate implicit in the lease whenever this rate is readily determinable. If the rate is not readily determinable in the lease, the Company used its incremental borrowing rate at lease inception, on a collateralized basis, over a similar term. March 31, 2020 December 31, 2019 Weighted-average remaining lease term Operating leases 12.5 12.7 Weighted-average discount rate Operating leases 2.29 % 2.34 % The components of the lease expense are as follows: (dollars in thousands) For the three months ended March 31, 2020 Operating lease cost $ 132 Short-term lease cost 17 Total $ 149 Future minimum payments for operating leases as of March 31, 2020 and December 31, 2019 were as follows: (dollars in thousands) March 31, 2020 December 31, 2019 Twelve Months Ended: Within one year $ 536 $ 440 After one but within two years 656 632 After two but within three years 623 583 After three but within four years 633 594 After four but within five years 616 596 After five years 4,210 4,164 Total Future Minimum Lease Payments 7,274 7,009 Amounts Representing Interest (978 ) (986 ) Present Value of Net Future Minimum Lease Payments $ 6,296 $ 6,023 |
Organization, Basis of Presen_2
Organization, Basis of Presentation and Recent Accounting Pronouncements (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim information and with the instructions to the Quarterly Report on Form 10-Q, as applicable to a smaller reporting company. Accordingly, they do not include all the information and footnotes required by US GAAP for complete financial statements. The financial statements are unaudited; but in the opinion of management include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation thereof. The balances as of December 31, 2019 have been derived from the audited consolidated financial statements. These financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto contained in the Annual Report on Form 10-KT filed by the Company with the U.S. Securities and Exchange Commission on March 27, 2020 The Company has evaluated subsequent events through the date of issuance of the financial statements included herein. Significant Event T he COVID-19 pandemic has adversely affected economic activity globally, nationally and locally. It has caused substantial disruption in international and U.S. economies, markets, and employment. In response to the COVID-19 national emergency, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was passed by Congress and signed into law by President Trump on March 27, 2020. The CARES Act provides an estimated $2.2 trillion of economy-wide financial stimulus to combat the pandemic and stimulate the economy in the form of financial aid to individuals, businesses, nonprofits, states, and municipalities through loans, grants, tax changes, and other types of relief. Some of the applicable provisions of the Cares Act to the Company include, but are not limited to • Accounting for Loan Modifications – Under Section 4013 of the CARES Act, a financial institution may elect to temporarily suspend (1) the requirements under GAAP for certain loan modifications that would otherwise be categorized as a Troubled Debt Restructuring (“TDR”) and (2) does not need to determine impairment associated with the loan modifications. As of March 31, 2020, the Company entered into four loan modification agreement with an outstanding balance of $1.2 million. As of April 20, 2020, the Company entered into a total of 19 loan modification agreements with respect to $6.9 million of loans outstanding. • Paycheck Protection Program - The CARES Act authorized the Small Business Administration (“SBA”) to temporarily guarantee loans under a new 7(a) loan program called the Paycheck Protection Program (“PPP”). In early April 2020, the Company began accepting and processing applications for loans under the Paycheck Protection Program. As of April 30, 2020, the Company had received over 330 applications from new and existing customers and disbursed approximately $48 million in funds with an estimated processing fee income of approximately $1.5 million. • Mortgage Forbearance - Under Section 4022 of the CARES Act, through the earlier of December 31, 2020, or the 60th day after the termination date of the COVID-19 national emergency, a borrower with a federally backed mortgage loan that is experiencing a financial hardship due to COVID-19 may request a forbearance, regardless of delinquency status, for up to 180 days, which must be extended for an additional 180 days at the borrower’s request. During this period, no fees, penalties, or interest beyond those scheduled or calculated as if the borrower had made all contractual payments on time and in full will accrue. A multifamily borrower with a federally backed multifamily mortgage loan that was current as of February 1, 2020, and is experiencing financial hardship due to COVID-19 may request forbearance on the loan for up to 30 days, with up to two additional 30-day periods at the borrower’s request. As of March 31, 2020, we received 17 deferral agreements with respect to $10.9 million of loans outstanding. As of April 30, 2020 we received a total of 54 deferral agreements with respect to $20.3 million of loans outstanding. For further discussion, see COVID-19 update section of Item 2-Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Principles of Consolidation | Principles of Consolidation The unaudited interim consolidated financial statements include accounts of the Company and its wholly-owned subsidiary, the Bank. All significant intercompany transactions and balances have been eliminated in consolidation. |
Use of Estimates in the Preparation of Financial Statements | Use of Estimates in the Preparation of Financial Statements In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the Statement of Financial Condition and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the determination of the allowance for loan losses, other-than-temporary impairments of securities (“OTTI”), interest rate lock commitments (“IRLCs”), mandatory sales commitments, the valuation of mortgage loans held-for-sale and the valuation of deferred tax assets. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Company qualifies under the Jumpstart Our Business Startups Act (the “JOBS Act”) as an emerging growth company. As an emerging growth company, the Company has elected to use the extended transition period to delay adoption of new or revised accounting pronouncements until such pronouncements are made applicable to private companies. In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires credit losses on most financial assets measured at amortized cost and certain other instruments to be measured using an expected credit loss model (referred to as the current expected credit loss (CECL) model). Under this model, entities will estimate credit losses over the entire contractual term of the instrument (considering estimated prepayments, but not expected extensions or modifications unless reasonable expectation of a troubled debt restructuring exists) from the date of initial recognition of that instrument. The ASU also replaces the current accounting model for purchased credit impaired loans and debt securities. The allowance for credit losses for purchased financial assets with a more-than insignificant amount of credit deterioration since origination (“PCD assets”), should be determined in a similar manner to other financial assets measured on an amortized cost basis. However, upon initial recognition, the allowance for credit losses is added to the purchase price (“gross up approach”) to determine the initial amortized cost basis. The subsequent accounting for PCD financial assets is the same expected loss model described above. Further, the ASU made certain targeted amendments to the existing impairment model for available-for-sale (“AFS”) debt securities. For an AFS debt security for which there is neither the intent nor a more-likely-than-not requirement to sell, an entity will record credit losses as an allowance rather than a write-down of the amortized cost basis. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019, and early adoption is permitted for annual and interim periods beginning after December 15, 2018. With certain exceptions, transition to the new requirements will be through a cumulative effect adjustment to opening retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments ‒ Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) We expect to recognize a one-time cumulative effect adjustment to the allowance for loan losses as of the beginning of the first reporting period in which the new standard is effective, but cannot yet determine the magnitude of any such one-time adjustment or the overall impact of the new guidance on the consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, Topic 326, Financial Instruments – Credit Losses Topic 815, Derivatives and Hedging Topic 825, Financial Instruments Financial Instruments ‒ Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) The Company qualifies as a smaller reporting company and does not expect to early adopt these ASUs. |
Adoption of New Accounting Standards | Adoption of New Accounting Standards In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes the Disclosure Requirements for Fair Value Measurements the Company’s consolidated statement of financial condition. |
Investment Securities (Tables)
Investment Securities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Investment Securities Available-for-Sale | Investment securities available-for-sale was comprised of the following: March 31, 2020 Gross Gross Amortized Unrealized Unrealized (Dollars in thousands) Cost Gains Losses Fair Value U.S. Governmental securities $ 420 $ 2 $ — $ 422 Corporate notes 9,286 143 (185 ) 9,244 Collateralized mortgage obligations - agency residential 6,168 69 (50 ) 6,187 Mortgage-backed securities - agency residential 3,864 99 — 3,963 Municipal securities 2,113 5 — 2,118 Bank CDs 1,248 18 — 1,266 $ 23,099 $ 336 $ (235 ) $ 23,200 Investment securities available-for-sale was comprised of the following: December 31, 2019 Gross Gross Amortized Unrealized Unrealized (Dollars in thousands) Cost Gains Losses Fair Value U.S. Governmental securities $ 438 $ — $ (2 ) $ 436 Corporate notes 5,500 75 (6 ) 5,569 Collateralized mortgage obligations - agency residential 6,562 4 (102 ) 6,464 Mortgage-backed securities - agency residential 4,070 12 (19 ) 4,063 Municipal securities 2,114 3 — 2,117 Bank CDs 2,498 9 — 2,507 $ 21,182 $ 103 $ (129 ) $ 21,156 |
Scheduled Maturities of Securities Available-for-Sale | The scheduled maturities of securities available-for-sale at March 31, 2020 March 31, 2020 Available-for-Sale Amortized (Dollars in thousands) Cost Fair Value Due in one year or less $ 1,875 $ 1,878 Due from one to five years 7,772 7,765 Due from after five to ten years 3,001 2,986 Due after ten years 10,451 10,571 $ 23,099 $ 23,200 |
Unrealized Loss Positions of Securities Available-for-Sale | The following tables summarize the unrealized loss positions of securities available-for-sale as of March 31, 2020 and December 31, 2019: March 31, 2020 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized (Dollars in thousands) Value Loss Value Loss Value Loss Available-for-sale: U.S. Governmental securities $ — $ — $ — $ — $ — $ — Corporate notes 1,479 (50 ) 2,365 (135 ) 3,844 (185 ) Collateralized mortgage obligations 960 (38 ) 1,392 (12 ) 2,352 (50 ) Mortgage-backed securities — — — — — — Municipal securities — — — — — — Bank CDs — — — — — — $ 2,439 $ (88 ) $ 3,757 $ (147 ) $ 6,196 $ (235 ) December 31, 2019 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized (Dollars in thousands) Value Loss Value Loss Value Loss Available-for-sale: U.S. Governmental securities $ — $ — $ 436 $ (2 ) $ 436 $ (2 ) Corporate notes — — 1,494 (6 ) 1,494 (6 ) Collateralized mortgage obligations 1,486 (10 ) 3,810 (92 ) 5,296 (102 ) Mortgage-backed securities 922 (7 ) 1,438 (12 ) 2,360 (19 ) Municipal securities — — — — — — Bank CDs — — 250 — 250 — $ 2,408 $ (17 ) $ 7,428 $ (112 ) $ 9,836 $ (129 ) |
Equity Securities (Tables)
Equity Securities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Schedule of Carrying Amount of Equity Investment | The following table presents the carrying amount of the Company’s equity investment at March 31, 2020 and December 31, 2019: March 31, 2020 (dollars in thousands) Year-to-date Life-to-date Amortized cost $ 500 $ 500 Impairment — — Observable price changes — — Carrying value $ 500 $ 500 December 31, 2019 (dollars in thousands) Year-to-date Life-to-date Amortized cost $ 500 $ 500 Impairment — — Observable price changes — — Carrying value $ 500 $ 500 |
Loans Receivable (Tables)
Loans Receivable (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Receivables [Abstract] | |
Summary of Loans Receivable | Loans receivable were comprised of the following: March 31, December 31, (Dollars in thousands) 2020 2019 Residential: One-to-four family $ 187,657 $ 197,547 Home equity and HELOCs 4,106 4,383 Commercial: Commercial real estate 38,795 35,188 Commercial business 14,349 11,119 Construction 2,090 784 Consumer: Medical education 5,953 6,097 Other 4 8 252,954 255,126 Unearned discounts, origination and commitment fees and costs 1,299 1,343 Allowance for loan losses (1,549 ) (1,437 ) $ 252,704 $ 255,032 |
Summary of Allowance for Loan Losses | The following tables summarize the activity in the allowance for loan losses by loan class for the three months ended March 31, 2020 and 2019. Allowance for Loan Losses For the three months ended March 31, 2020 (Dollars in thousands) Beginning Balance Charge- offs Recoveries (Credit) Provisions Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairments Residential: One-to-four family $ 701 $ — $ — $ 59 $ 760 $ — $ 760 Home equity and HELOCs 44 — — (31 ) 13 — 13 Commercial: Commercial real estate 229 — — 40 269 — 269 Commercial business 122 — — 32 154 — 154 Construction 8 — — 14 22 — 22 Consumer: Medical education 333 — 1 (3 ) 331 — 331 Other — — — — — — $ 1,437 $ — $ 1 $ 111 $ 1,549 $ — $ 1,549 Allowance for Loan Losses For the three months ended March 31, 2019 (Dollars in thousands) Beginning Balance Charge- offs Recoveries (Credit) Provisions Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairments Residential: One-to-four family $ 722 $ — $ — $ 7 $ 729 $ — $ 729 Home equity and HELOCs 46 — — — 46 — 46 Commercial: Commercial real estate 59 — — 2 61 — 61 Commercial business 59 — — 7 66 13 53 Construction 13 — — 2 15 — 15 Consumer: Medical education 56 (141 ) — 223 138 — 138 Other 1 (1 ) — — — — — $ 956 $ (142 ) $ — $ 241 $ 1,055 $ 13 $ 1,042 |
Summary of Loans Receivable by Balances Individually Evaluated for Impairment | The following tables summarize information in regard to the recorded investment in loans receivable by loan class as of March 31, 2020 and December 31, 2019: March 31, 2020 Loans Receivable (Dollars in thousands) Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairment Residential One-to-four family $ 187,657 $ 1,539 $ 186,118 Home equity and HELOCs 4,106 279 3,827 Commercial Commercial real estate 38,795 313 38,482 Commercial business 14,349 114 14,235 Construction 2,090 — 2,090 Consumer: Medical education 5,953 — 5,953 Other 4 — 4 $ 252,954 $ 2,245 $ 250,709 December 31, 2019 Loans Receivable (Dollars in thousands) Ending Balance Ending Balance: Individually Evaluated for Impairment Ending Balance: Collectively Evaluated for Impairment Residential One-to-four family $ 197,547 $ 1,566 $ 195,981 Home equity and HELOCs 4,383 308 4,075 Commercial Commercial real estate 35,188 317 34,871 Commercial business 11,119 120 10,999 Construction 784 — 784 Consumer: Medical education 6,097 — 6,097 Other 8 — 8 $ 255,126 $ 2,311 $ 252,815 |
Summary of Information in Regard to Impaired Loans | The following table summarizes information about impaired loans by loan portfolio class as of March 31, 2020 and December 31, 2019 March 31, 2020 December 31, 2019 (Dollars in thousands) Recorded Investment Unpaid Principal Balance Related Allowance Recorded Investment Unpaid Principal Balance Related Allowance With no related allowance recorded Residential: One-to-four family $ 1,539 $ 1,692 $ — $ 1,566 $ 1,703 $ — Home equity and HELOCs 55 76 — 308 308 — Commercial: Commercial real estate 313 313 — 317 317 — Commercial business 114 114 — — — — Consumer: Medical education — — — — — — 2,021 2,195 — 2,191 2,328 — With an allowance recorded Residential: Home equity and HELOCs 224 227 1 — — — Commercial: Commercial business — — — 120 121 12 224 227 1 120 121 12 $ 2,245 $ 2,422 $ 1 $ 2,311 $ 2,449 $ 12 The following table presents additional information regarding the impaired loans for the three months ended March 31, 2020 and Three Months Ended March 31, 2020 2019 (Dollars in thousands) Average Record Investment Interest Income Recognized Average Record Investment Interest Income Recognized With no related allowance recorded Residential: One-to-four family $ 1,552 $ — $ 1,425 $ — Home equity and HELOCs 294 — 67 — Commercial: Commercial real estate 315 6 388 7 Commercial business 117 2 — — Consumer: Medical education — — 258 — 2,278 8 2,138 7 With an allowance recorded Commercial business — — 139 2 — — 139 2 $ 2,278 $ 8 $ 2,277 $ 9 |
Summary of Nonaccrual Loans by Classes of Loan Portfolio | The following table presents nonaccrual loans by classes of the loan portfolio as of March 31, 2020 and December 31, 2019 March 31, December 31, (Dollars in thousands) 2020 2019 Residential: One-to-four family $ 1,656 $ 1,686 Home equity and HELOCs 279 308 Commercial: Commercial real estate — — Commercial business — — Construction — — Consumer: Medical education 1,849 1,710 Other — — $ 3,784 $ 3,704 |
Credit Quality Indicators by Class of Loan Portfolio | The following tables summarize the aggregate Pass and criticized categories of Special Mention, Substandard and Doubtful within the Company’s internal risk rating system as of March 31, 2020 and December 31, 2019: March 31, 2020 Special (Dollars in thousands) Pass Mention Substandard Doubtful Total Residential: One-to-four family $ 186,001 $ — $ 1,656 $ — $ 187,657 Home equity and HELOCs 3,827 — 279 — 4,106 Commercial: Commercial real estate 38,281 201 313 — 38,795 Commercial business 14,170 — 179 — 14,349 Construction 2,090 — — — 2,090 Consumer: Medical education 4,104 — 1,849 — 5,953 Other 4 — — — 4 $ 248,477 $ 201 $ 4,276 $ — $ 252,954 December 31, 2019 Special (Dollars in thousands) Pass Mention Substandard Doubtful Total Residential: One-to-four family $ 195,861 $ — $ 1,686 $ — $ 197,547 Home equity and HELOCs 4,075 — 308 — 4,383 Commercial: Commercial real estate 34,667 204 317 — 35,188 Commercial business 10,924 — 195 — 11,119 Construction 784 — — — 784 Consumer: Medical education 4,387 — 1,710 — 6,097 Other 8 — — — 8 $ 250,706 $ 204 $ 4,216 $ — $ 255,126 |
Summary of Segments of Loan Portfolio by Aging Categories | The following tables present the segments of the loan portfolio summarized by aging categories as of March 31, 2020 and December 31, 2019: March 31, 2020 (Dollars in thousands) 30-59 Days Past Due 60-89 Days Past Due Greater than 90 Days Total Past Due Current Total Loans Receivable Loans Receivable >90 Days and Accruing Residential: One-to-four family $ 475 $ 656 $ 299 $ 1,430 $ 186,227 $ 187,657 $ — Home equity and HELOCs — 71 — 71 4,035 4,106 — Commercial: Commercial real estate — — — — 38,795 38,795 — Commercial business — — — — 14,349 14,349 — Construction — — — — 2,090 2,090 — Consumer: Medical education 358 243 460 1,061 4,892 5,953 — Other — — — — 4 4 — $ 833 $ 970 $ 759 $ 2,562 $ 250,392 $ 252,954 $ — December 31, 2019 (Dollars in thousands) 30-59 Days Past Due 60-89 Days Past Due Greater than 90 Days Total Past Due Current Total Loans Receivable Loans Receivable >90 Days and Accruing Residential: One-to-four family $ 365 $ 94 $ 359 $ 818 $ 196,729 $ 197,547 $ — Home equity and HELOCs — — — — 4,383 4,383 — Commercial: Commercial real estate — — — — 35,188 35,188 — Commercial business — — — — 11,119 11,119 — Construction — — — — 784 784 — Consumer: Medical education 103 53 709 865 5,232 6,097 — Other — — — — 8 8 — $ 468 $ 147 $ 1,068 $ 1,683 $ 253,443 $ 255,126 $ — |
Summary of Troubled Debt Restructurings on Accrual Status and Non-Accrual Status | The following table details the Company’s TDRs that are on accrual status and non-accrual status at March 31, 2020: As of March 31, 2020 Number Accrual Non-Accrual (Dollars in thousands) Of Loans Status Status Total TDRs Commercial real estate 1 $ 137 $ — $ 137 Commercial business 1 114 — 114 Total 2 $ 251 $ — $ 251 The following table details the Company’s TDRs that are on accrual status and non-accrual status at December 31, 2019: As of December 31, 2019 Number Accrual Non-Accrual (Dollars in thousands) Of Loans Status Status Total TDRs Commercial real estate 1 $ 139 $ — $ 139 Commercial business 1 120 — 120 Total 2 $ 259 $ — $ 259 |
Derivatives and Risk Manageme_2
Derivatives and Risk Management Activities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Derivatives Not Designated as Hedging Instruments Recorded in Consolidated Statement of Financial Condition | The following tables summarize the amounts recorded in the Company’s consolidated statements of financial condition for derivatives not designated as hedging instruments as of March 31, 2020 and December 31, 2019 (in thousands): March 31, 2020 Asset Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Mortgage banking derivatives $ 1,939 $ 102,349 Forward loan sales commitments Mortgage banking derivatives 297 7,266 To Be Announced securities ("TBAs") Mortgage banking derivatives — — Liability Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Other liabilities $ 32 $ 4,815 Forward loan sales commitments Other liabilities 87 8,863 TBA securities Other liabilities 655 26,000 December 31, 2019 Asset Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Mortgage banking derivatives $ 810 $ 25,059 Forward loan sales commitments Mortgage banking derivatives 389 11,036 TBA securities Mortgage banking derivatives 5 3,500 Liability Derivatives Balance Sheet Notional Presentation Fair Value Amount Interest rate lock commitments Other liabilities $ 25 $ 3,820 Forward loan sales commitments Other liabilities 45 10,595 TBA securities Other liabilities 56 24,500 |
Summary of Amounts Recorded in Consolidated Statements of Income for Derivative Instruments Not Designated as Hedging Instruments | The following table summarizes the amounts recorded in the Company’s consolidated statements of income for derivative instruments not designated as hedging instruments for the three months ended March 31, 2020 and 2019 (in thousands): Gain Consolidated Statements of Income Three Months Ended Presentation March 31, 2020 March 31, 2019 Interest rate lock commitments Gain from derivative instruments $ 1,122 $ 453 Forward loan sales commitments Loss from derivative instruments (134 ) (14 ) TBA securities Loss from derivative instruments (604 ) (44 ) Total gain from derivative instruments $ 384 $ 395 |
Fair Value Presentation (Tables
Fair Value Presentation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value for Assets Required to be Measured and Reported at Fair Value on a Recurring Basis | The following tables provide the fair value for assets required to be measured and reported at fair value on a recurring basis as of March 31, 2020 and December 31, 2019: March 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Investment securities available-for-sale: U.S. Governmental securities $ — $ 422 $ — $ 422 Corporate notes — 6,211 3,033 9,244 Collateralized mortgage obligations - agency residential — 6,187 — 6,187 Mortgage-backed securities - agency residential — 3,963 — 3,963 Municipal securities — 2,118 — 2,118 Bank CDs — 1,266 — 1,266 Loans held for sale — 37,368 — 37,368 Interest rate lock commitments — — 1,939 1,939 Forward loan sales commitments — 297 — 297 TBA securities — — — — $ — $ 57,832 $ 4,972 $ 62,804 December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Investment securities available-for-sale: U.S. Governmental securities $ — $ 436 $ — $ 436 Corporate notes — 2,510 3,059 5,569 Collateralized mortgage obligations - agency residential — 6,464 — 6,464 Mortgage-backed securities - agency residential — 4,063 — 4,063 Municipal securities — 2,117 — 2,117 Bank CDs — 2,507 — 2,507 Loans held for sale — 37,876 — 37,876 Interest rate lock commitments — — 810 810 Forward loan sales commitments — 389 — 389 TBA securities — 5 — 5 $ — $ 56,367 $ 3,869 $ 60,236 |
Fair Value for Liabilities Required to be Measured and Reported at Fair Value on a Recurring Basis | The following tables provide the fair value for liabilities required to be measured and reported at fair value on a recurring basis as of March 31, 2020 and December 31, 2019. March 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Interest rate lock commitments $ — $ — $ 32 $ 32 Forward loan sales commitments — 87 — 87 TBA securities — 655 — 655 $ — $ 742 $ 32 $ 774 December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Interest rate lock commitments $ — $ — $ 25 $ 25 Forward loan sales commitments — 45 — 45 TBA securities — 56 — 56 $ — $ 101 $ 25 $ 126 |
Change in Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) | The following tables represent the change in the assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three ended March 31, 2020 and 2019: (Dollars in thousands) Corporate notes IRLC- Asset IRLC- Liability Beginning Balance: January 1, 2020 $ 3,059 $ 810 $ (25 ) Total unrealized losses: Included in other comprehensive income (26 ) — — Total gains or (losses) included in earnings and held at reporting date — 1,129 (7 ) Transfers in and/or out of Level 3 — — — Ending Balance: March 31, 2020 $ 3,033 $ 1,939 $ (32 ) Change in unrealized gains or (losses) for the period included in earnings (or changes in net assets) for assets held as of March 31, 2020 — 1,129 (7 ) Change in unrealized gains for the period included other comprehensive income for assets held as of March 31, 2020 $ 26 $ — $ — (Dollars in thousands) Corporate notes IRLC- Asset IRLC- Liability Beginning Balance: January 1, 2019 $ 494 $ 218 $ (18 ) Total unrealized losses: Included in other comprehensive income (2 ) — — Total gains or (losses) included in earnings and held at reporting date — 462 (9 ) Transfers in and/or out of Level 3 — — — Ending Balance: March 31, 2019 $ 492 $ 680 $ (27 ) |
Significant Unobservable Inputs for Assets and Liabilities Measured at Fair Value on a Recurring Basis | Significant unobservable inputs for assets and liabilities measured at fair value on a recurring basis at March 31, 2020: Quantitative Information about Level 3 Fair Value Measurements at March 31, 2020 (Dollars in thousands) Fair Value Valuation Technique Significant Unobservable Input Range Weighted Average Measured at Fair Value on a Recurring Basis: Corporate notes $ 1,033 Pricing model Market quotes $92.37-$104.66 $ 101.24 $ 2,000 Market comparable securities Market quotes $ 102.00 $ 102.00 Net derivative asset and liability: IRLC $ 1,939 Discounted cash flows Pull-through rates 25%-98% 77% |
Carrying Amount for Class of Assets and Liabilities and Fair Value for Certain Financial Instruments Not Required to be Measured or Reported at Fair Value | The following table provides the carrying amount for each class of assets and liabilities and the fair value for certain financial instruments that are not required to be measured or reported at fair value on the Consolidated Statements of Financial Condition as of March 31, 2020 and December 31, 2019: Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable March 31, 2020 Carrying Estimated Assets Inputs Inputs (Dollars in thousands) Amount Fair Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 20,515 $ 20,515 $ 20,515 $ — $ — Equity securities 500 500 — — 500 Loans receivable, net (1) 252,704 260,389 — — 260,389 Bank-owned life insurance 6,293 6,293 6,293 — — Restricted investment in bank stock 1,751 1,751 1,751 — — Accrued interest receivable 1,112 1,112 1,112 — — Liabilities: Deposits $ 278,185 $ 278,599 $ 216,372 $ 62,227 $ — Advances from the FHLB 32,000 32,692 5,000 27,692 — Advances from borrowers for taxes and insurance 1,936 1,936 1,936 — — Accrued interest payable 186 186 186 — — Off-balance sheet: Commitment to extend credit $ — $ — $ — $ — $ — (1) In accordance with the prospective adoption of ASU No. 2016-01, the fair value of the loans as of September 30, 2019 and June 30, 2019 were measured using an exit price notion. Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable December 31, 2019 Carrying Estimated Assets Inputs Inputs (Dollars in thousands) Amount Fair Value Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 20,625 $ 20,625 $ 20,625 $ — $ — Equity securities 500 500 — — 500 Loans receivable, net (1) 255,032 254,884 — — 254,884 Bank-owned life insurance 6,255 6,255 6,255 — — Restricted investment in bank stock 1,552 1,552 1,552 — — Accrued interest receivable 967 967 967 — — Liabilities: Deposits $ 283,767 $ 284,055 $ 215,471 $ 68,584 $ — Advances from the FHLB 27,000 27,333 — 27,333 — Advances from borrowers for taxes and insurance 2,138 2,138 2,138 — — Accrued interest payable 305 305 305 — — Off-balance sheet: Commitment to extend credit $ — $ — $ — $ — $ — |
Changes in and Reclassificati_2
Changes in and Reclassifications out of Accumulated Other Comprehensive Gain (Loss) (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Schedule of Changes in Component of Accumulated Other Comprehensive Income (Loss), Net of Tax | The following tables present the changes in the balances of each component of accumulated other comprehensive income (loss) (“AOCI”) for the three months ended March 31, 2020 and March 31, 2019 Net unrealized holding gains on available-for-sales securities (1) For the three months ended (Dollars in thousands) March 31, 2020 March 31, 2019 Balance at beginning period $ (18 ) $ (548 ) Unrealized holding gain on available-for-sale securities before reclassification 89 249 Amount reclassified for investment securities gains included in net income — (3 ) Net current-period other comprehensive income 89 246 Balance at ending period $ 71 $ (302 ) (1) All amounts are net of tax. Related tax expense or benefit is calculated using an income tax rate of approximately 29.5% and 28.2% for the three months ended March 31, 2020 and 2019, respectively. |
Reclassifications out of AOCI by Component | The following table present reclassifications out of AOCI by component for the three months ended March 31, 2020 and March 31, 2019. For the three months ended March 31, 2020 For the three months ended March 31, 2019 (Dollars in thousands) Amount reclassified from accumulated other comprehensive income (loss) (2) Amount reclassified from accumulated other comprehensive income (loss) (2) Affected line item in the consolidated statements of income Net realized gain on available-for securities (1) $ — $ 4 Gain on sale of available-for-sale securities, net Tax Effect — (1) Income tax expense $ — $ 3 (1) For additional details related to unrealized gains on investment securities and related amounts reclassified from accumulated other comprehensive loss, See Note 2, “Investment securities.” (2) Amounts in parentheses indicate debits. |
Earnings per Share (Tables)
Earnings per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Earnings Per Share | The calculation of basic and diluted EPS for the three For the Three Months Ended March 31 2020 2019 Net income $ 149,000 $ 62,000 Weighted average number of shares issued 2,270,180 2,261,258 Less weighted average number of treasury shares (2,487 ) — Less weighted average number of unearned ESOP shares (146,954 ) (155,682 ) Less weighted average number of unvested restricted stock awards (67,050 ) (75,207 ) Basic weighted average shares outstanding 2,053,689 2,030,369 Add dilutive effect of stock options 75 — Add dilutive effect of restricted stock awards — — Diluted weighted average shares outstanding 2,053,764 2,030,369 Net income per share: Basic $ 0.07 $ 0.03 Diluted $ 0.07 $ 0.03 |
Employee Benefits (Tables)
Employee Benefits (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract] | |
Summary of Stock Option Activity | A summary of the Company’s stock option activity and related information for the three months ended March 31, 2020 and March 31, 2019 was as follows: March 31, 2020 March 31, 2019 Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Average Intrinsic Value Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Average Intrinsic Value Outstanding, Jan 1 218,000 $ 14.92 8.6 $ 452,400 188,000 $ 14.80 9.4 $ 33,840 Granted — — — — 10,000 15.28 9.9 — Exercised (1,600 ) 14.82 — — — — — — Forfeited — — — — — — — — Outstanding, March 31 216,400 $ 14.93 8.4 $ — 198,000 $ 14.82 9.6 $ 253,440 Exercisable, March 31 30,080 $ 14.83 8.3 $ — — $ — — $ — |
Summary of Restricted Stock Activity | A summary of the Company’s restricted stock activity and related information for the three months ended March 31, 2020 and 2019 was as follows: March 31, 2020 March 31, 2019 Number of Shares Weighted- Average Grant Date Fair Value Number of Shares Weighted- Average Grant Date Fair Value Non-vested, Jan 1 75,320 $ 14.97 73,000 $ 14.80 Vested (640 ) 15.21 — — Granted — — 4,000 15.21 Forfeited — — — — Non-vested at March 31 74,680 $ 14.97 77,000 $ 14.82 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Revenue From Contract With Customer [Abstract] | |
Summary of Noninterest Income | The following table presents noninterest income for the three months ended March 31, 2020 and March 31, 2019: Three Months Ended March 31, (Dollars in thousands) 2020 2019 Non-Interest Income In-scope of Topic 606: Fee income $ 3 $ 5 Insufficient fund fees 17 12 Other service charges 17 11 ATM interchange fee income 2 2 Total Non-Interest Income (in-scope of Topic 606) $ 39 $ 30 Out-of-scope of Topic 606: Increase in cash surrender value of bank-owned life insurance $ 38 $ 39 Gain on sale of loans, net 1,629 890 Gain on sale of available-for-sale securities — 4 Gain from derivative instruments 384 395 Change in fair value for loans held-for-sale 6 (376 ) Other 48 4 Total Non-Interest Income (out-scope of Topic 606) 2,105 956 Total Non-Interest Income (in-scope of Topic 606) 39 30 Total Noninterest Income $ 2,144 $ 986 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Consolidated Statement of Financial Condition Classification of ROU Assets and Lease Liabilities | The following table represents the classification of the Company’s ROU assets and lease liabilities in the consolidated statements of financial condition: March 31, 2020 December 31, 2019 Lease Right-of-Use Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets $ 6,187 $ 5,979 Total Lease Right-of-Use Assets $ 6,187 $ 5,979 March 31, 2020 December 31, 2019 Lease Liabilities Classification Operating lease liabilities Operating lease liabilities $ 6,296 $ 6,023 Total Lease Liabilities $ 6,296 $ 6,023 |
Summary of Weighted Average Lease Term and Discount Rate | March 31, 2020 December 31, 2019 Weighted-average remaining lease term Operating leases 12.5 12.7 Weighted-average discount rate Operating leases 2.29 % 2.34 % |
Components of Lease Expense | The components of the lease expense are as follows: (dollars in thousands) For the three months ended March 31, 2020 Operating lease cost $ 132 Short-term lease cost 17 Total $ 149 |
Schedule of Future Payments for Operating Lease | Future minimum payments for operating leases as of March 31, 2020 and December 31, 2019 were as follows: (dollars in thousands) March 31, 2020 December 31, 2019 Twelve Months Ended: Within one year $ 536 $ 440 After one but within two years 656 632 After two but within three years 623 583 After three but within four years 633 594 After four but within five years 616 596 After five years 4,210 4,164 Total Future Minimum Lease Payments 7,274 7,009 Amounts Representing Interest (978 ) (986 ) Present Value of Net Future Minimum Lease Payments $ 6,296 $ 6,023 |
Organization, Basis of Presen_3
Organization, Basis of Presentation and Recent Accounting Pronouncements - Additional Information (Details) $ in Thousands | Apr. 20, 2020USD ($)Loan | Mar. 31, 2020USD ($)LoanAgreement | Mar. 27, 2020USD ($) | Mar. 31, 2020USD ($)LoanAgreement | Dec. 31, 2019USD ($)Loan | Apr. 30, 2020USD ($)LoanAgreement |
Financing Receivable Recorded Investment [Line Items] | ||||||
CARES act authorized amount of fund | $ 2,200 | |||||
Number of loan modification agreement | Loan | 2 | 2 | ||||
Loan modification agreement amount | $ 251 | $ 251 | $ 259 | |||
CARES Act | ||||||
Financing Receivable Recorded Investment [Line Items] | ||||||
Number of loan modification agreement | Loan | 4 | |||||
Loan modification agreement amount | $ 1,200 | $ 1,200 | ||||
Number of deferral agreements | Agreement | 17 | 17 | ||||
Mortgage loan forbearance amount | $ 10,900 | $ 10,900 | ||||
Subsequent Event | CARES Act | ||||||
Financing Receivable Recorded Investment [Line Items] | ||||||
Number of loan modification agreement | Loan | 19 | |||||
Loan modification agreement amount | $ 6,900 | |||||
Number of deferral agreements | Agreement | 54 | |||||
Mortgage loan forbearance amount | $ 20,300 | |||||
Subsequent Event | CARES Act | Paycheck Protection Program | ||||||
Financing Receivable Recorded Investment [Line Items] | ||||||
Number of loans processed | Loan | 330 | |||||
Loans amount funded | $ 48,000 | |||||
Loans amount funded processing fee income | $ 1,500 |
Investment Securities - Investm
Investment Securities - Investment Securities Available-for-sale (Detail) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | $ 23,099,000 | $ 21,182,000 |
Available-for-sale, Gross Unrealized Gains | 336,000 | 103,000 |
Available-for-sale, Gross Unrealized Losses | (235,000) | (129,000) |
Available-for-sale, Fair Value | 23,200,000 | 21,156,000 |
U.S. Governmental securities | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 420,000 | 438,000 |
Available-for-sale, Gross Unrealized Gains | 2,000 | |
Available-for-sale, Gross Unrealized Losses | (2,000) | |
Available-for-sale, Fair Value | 422,000 | 436,000 |
Corporate notes | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 9,286,000 | 5,500,000 |
Available-for-sale, Gross Unrealized Gains | 143,000 | 75,000 |
Available-for-sale, Gross Unrealized Losses | (185,000) | (6,000) |
Available-for-sale, Fair Value | 9,244,000 | 5,569,000 |
Collateralized mortgage obligations - agency residential | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 6,168,000 | 6,562,000 |
Available-for-sale, Gross Unrealized Gains | 69,000 | 4,000 |
Available-for-sale, Gross Unrealized Losses | (50,000) | (102,000) |
Available-for-sale, Fair Value | 6,187,000 | 6,464,000 |
Mortgage-backed securities - agency residential | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 3,864,000 | 4,070,000 |
Available-for-sale, Gross Unrealized Gains | 99,000 | 12,000 |
Available-for-sale, Gross Unrealized Losses | (19,000) | |
Available-for-sale, Fair Value | 3,963,000 | 4,063,000 |
Municipal securities | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 2,113,000 | 2,114,000 |
Available-for-sale, Gross Unrealized Gains | 5,000 | 3,000 |
Available-for-sale, Fair Value | 2,118,000 | 2,117,000 |
Bank CDs | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale, Amortized Cost | 1,248,000 | 2,498,000 |
Available-for-sale, Gross Unrealized Gains | 18,000 | 9,000 |
Available-for-sale, Fair Value | $ 1,266,000 | $ 2,507,000 |
Investment Securities - Schedul
Investment Securities - Scheduled of Maturities of Securities Available-for-sale (Detail) $ in Thousands | Mar. 31, 2020USD ($) |
Investments Debt And Equity Securities [Abstract] | |
Available-for-Sale, Due in one year or less, Amortized Cost | $ 1,875 |
Available-for-Sale, Due from one to five years, Amortized Cost | 7,772 |
Available-for-Sale, Due from after five to ten years, Amortized Cost | 3,001 |
Available-for-Sale, Due after ten years, Amortized Cost | 10,451 |
Available-for-Sale, Amortized Cost | 23,099 |
Available-for-Sale, Due in one year or less, Fair Value | 1,878 |
Available-for-Sale, Due from one to five years, Fair Value | 7,765 |
Available-for-Sale, Due from after five to ten years, Fair Value | 2,986 |
Available-for-Sale, Due after ten years, Fair Value | 10,571 |
Available-for-Sale, Fair Value | $ 23,200 |
Investment Securities - Additio
Investment Securities - Additional information (Detail) | 3 Months Ended | ||
Mar. 31, 2020USD ($)Security | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($)Security | |
Investment Holdings [Line Items] | |||
Securities with a fair value pledge to secure public deposits and for other purposes as required by law | $ 7,200,000 | $ 7,400,000 | |
Proceeds from the sale of available-for-sale securities | 0 | $ 1,956,000 | |
Gross realized gains on sale of available-for-sale securities | 0 | 4,000 | |
Gross realized losses sale of available-for-sale securities | 0 | $ 0 | |
Securities available-for-sale, fair value | $ 23,200,000 | $ 21,156,000 | |
Bank CDs | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 5 | 10 | |
Securities available-for-sale, fair value | $ 1,266,000 | $ 2,507,000 | |
Number of securities with unrealized losses | Security | 0 | 1 | |
U.S. Governmental securities | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 2 | 2 | |
Securities available-for-sale, fair value | $ 422,000 | $ 436,000 | |
Number of securities with unrealized losses | Security | 0 | 2 | |
Corporate notes | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 15 | 9 | |
Securities available-for-sale, fair value | $ 9,244,000 | $ 5,569,000 | |
Investment securities | $ 9,200,000 | $ 5,600,000 | |
Number of securities with unrealized losses | Security | 7 | 3 | |
Collateralized mortgage obligations | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 30 | 30 | |
Securities available-for-sale, fair value | $ 6,187,000 | $ 6,464,000 | |
Number of securities with unrealized losses | Security | 12 | 27 | |
Available for sale securities percentage of agency | 100.00% | ||
Mortgage-backed securities | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 13 | 13 | |
Securities available-for-sale, fair value | $ 3,963,000 | $ 4,063,000 | |
Number of securities with unrealized losses | Security | 0 | 7 | |
Available for sale securities percentage of agency | 100.00% | ||
Municipal securities | |||
Investment Holdings [Line Items] | |||
Number of investment securities | Security | 5 | 5 | |
Securities available-for-sale, fair value | $ 2,118,000 | $ 2,117,000 | |
Number of securities with unrealized losses | Security | 0 | 0 | |
Investment securities | $ 2,100,000 | $ 2,100,000 |
Investment Securities - Unreali
Investment Securities - Unrealized Loss Positions of Securities Available-for-Sale (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Investment Holdings [Line Items] | ||
Available-for-sale, Less than 12 Months, Fair Value | $ 2,439 | $ 2,408 |
Available-for-sale, Less than 12 Months, Unrealized Loss | (88) | (17) |
Available-for-sale, 12 Months or Longer, Fair Value | 3,757 | 7,428 |
Available-for-sale, 12 Months or Longer, Unrealized Loss | (147) | (112) |
Available-for-sale, Total, Fair Value | 6,196 | 9,836 |
Available-for-sale, Total, Unrealized Loss | (235) | (129) |
U.S. Governmental securities | ||
Investment Holdings [Line Items] | ||
Available-for-sale, 12 Months or Longer, Fair Value | 436 | |
Available-for-sale, 12 Months or Longer, Unrealized Loss | (2) | |
Available-for-sale, Total, Fair Value | 436 | |
Available-for-sale, Total, Unrealized Loss | (2) | |
Corporate notes | ||
Investment Holdings [Line Items] | ||
Available-for-sale, Less than 12 Months, Fair Value | 1,479 | |
Available-for-sale, Less than 12 Months, Unrealized Loss | (50) | |
Available-for-sale, 12 Months or Longer, Fair Value | 2,365 | 1,494 |
Available-for-sale, 12 Months or Longer, Unrealized Loss | (135) | (6) |
Available-for-sale, Total, Fair Value | 3,844 | 1,494 |
Available-for-sale, Total, Unrealized Loss | (185) | (6) |
Collateralized mortgage obligations | ||
Investment Holdings [Line Items] | ||
Available-for-sale, Less than 12 Months, Fair Value | 960 | 1,486 |
Available-for-sale, Less than 12 Months, Unrealized Loss | (38) | (10) |
Available-for-sale, 12 Months or Longer, Fair Value | 1,392 | 3,810 |
Available-for-sale, 12 Months or Longer, Unrealized Loss | (12) | (92) |
Available-for-sale, Total, Fair Value | 2,352 | 5,296 |
Available-for-sale, Total, Unrealized Loss | $ (50) | (102) |
Mortgage-backed securities | ||
Investment Holdings [Line Items] | ||
Available-for-sale, Less than 12 Months, Fair Value | 922 | |
Available-for-sale, Less than 12 Months, Unrealized Loss | (7) | |
Available-for-sale, 12 Months or Longer, Fair Value | 1,438 | |
Available-for-sale, 12 Months or Longer, Unrealized Loss | (12) | |
Available-for-sale, Total, Fair Value | 2,360 | |
Available-for-sale, Total, Unrealized Loss | (19) | |
Bank CDs | ||
Investment Holdings [Line Items] | ||
Available-for-sale, 12 Months or Longer, Fair Value | 250 | |
Available-for-sale, Total, Fair Value | $ 250 |
Equity Securities - Additional
Equity Securities - Additional information (Detail) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Investments Debt And Equity Securities [Abstract] | ||
Purchase of equity securities | $ 500,000 | $ 500,000 |
Equity Securities - Schedule of
Equity Securities - Schedule of Carrying Amount of Equity Investment (Detail) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Investments Debt And Equity Securities [Abstract] | ||
Amortized cost | $ 500,000 | $ 500,000 |
Carrying value | $ 500,000 | $ 500,000 |
Loans Receivable - Summary of L
Loans Receivable - Summary of Loans Receivable (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | $ 252,954 | $ 255,126 | ||
Unearned discounts, origination and commitment fees and costs | 1,299 | 1,343 | ||
Allowance for loan losses | (1,549) | (1,437) | $ (1,055) | $ (956) |
Loans and leases receivable, net amount | 252,704 | 255,032 | ||
Residential | 1-4 family | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 187,657 | 197,547 | ||
Allowance for loan losses | (760) | (701) | (729) | (722) |
Residential | Home equity and HELOCs | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 4,106 | 4,383 | ||
Allowance for loan losses | (13) | (44) | (46) | (46) |
Commercial | Commercial Real Estate | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 38,795 | 35,188 | ||
Allowance for loan losses | (269) | (229) | (61) | (59) |
Commercial | Commercial Business | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 14,349 | 11,119 | ||
Allowance for loan losses | (154) | (122) | (66) | (59) |
Construction | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 2,090 | 784 | ||
Allowance for loan losses | (22) | (8) | (15) | (13) |
Consumer | Medical Education | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | 5,953 | 6,097 | ||
Allowance for loan losses | (331) | (333) | $ (138) | (56) |
Consumer | Other | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Loans and leases receivable, gross | $ 4 | $ 8 | ||
Allowance for loan losses | $ (1) |
Loans Receivable - Additional I
Loans Receivable - Additional Information (Detail) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020USD ($)Loan | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($)Loan | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Loans receivable, balance | $ 252,954,000 | $ 255,126,000 | |
Balance of loans past due 90 days or more | 2,562,000 | 1,683,000 | |
Overdrafts | 4,000 | $ 8,000 | |
Loans performing under original contractual, interest increase | $ 24,000 | $ 22,000 | |
Number of loans identified as TDRs | Loan | 2 | 2 | |
Loans identified as TDRs | $ 251,000 | $ 259,000 | |
Modifications to loans classified as TDRs | 0 | $ 0 | |
Additional loan commitments outstanding | 0 | 0 | |
Specific reserve related to TDR | 0 | 12,000 | |
Residential Mortgage | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Mortgage loans in process of foreclosure | 394,000 | 403,000 | |
Financing Receivables, Equal to Greater than 90 Days Past Due | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Balance of loans past due 90 days or more | 759,000 | 1,068,000 | |
Medical Education | Consumer | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Loans receivable, balance | 5,953,000 | 6,097,000 | |
Balance of loans past due 90 days or more | $ 1,061,000 | 865,000 | |
Medical Education | Financing Receivables, Equal to Greater than 90 Days Past Due | Consumer | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Number of loans | Loan | 8 | ||
Balance of loans past due 90 days or more | $ 460,000 | $ 709,000 |
Loans Receivable - Summary of A
Loans Receivable - Summary of Activity in Allowance for Loan Losses By Loan Class (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | $ 1,437 | $ 956 |
Allowance for Loan Losses Charge-offs | (142) | |
Allowance for Loan Losses Recoveries | 1 | |
Allowance for Loan Losses (Credit) Provisions | 111 | 241 |
Allowance for Loan Losses Ending Balance | 1,549 | 1,055 |
Allowance for Loan Losses Ending Balance Individually Evaluated for Impairment | 13 | |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 1,549 | 1,042 |
Residential | 1-4 family | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 701 | 722 |
Allowance for Loan Losses (Credit) Provisions | 59 | 7 |
Allowance for Loan Losses Ending Balance | 760 | 729 |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 760 | 729 |
Residential | Home equity and HELOCs | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 44 | 46 |
Allowance for Loan Losses (Credit) Provisions | (31) | |
Allowance for Loan Losses Ending Balance | 13 | 46 |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 13 | 46 |
Commercial | Commercial Real Estate | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 229 | 59 |
Allowance for Loan Losses (Credit) Provisions | 40 | 2 |
Allowance for Loan Losses Ending Balance | 269 | 61 |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 269 | 61 |
Commercial | Commercial Business | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 122 | 59 |
Allowance for Loan Losses (Credit) Provisions | 32 | 7 |
Allowance for Loan Losses Ending Balance | 154 | 66 |
Allowance for Loan Losses Ending Balance Individually Evaluated for Impairment | 13 | |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 154 | 53 |
Construction | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 8 | 13 |
Allowance for Loan Losses (Credit) Provisions | 14 | 2 |
Allowance for Loan Losses Ending Balance | 22 | 15 |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | 22 | 15 |
Consumer | Medical Education | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 333 | 56 |
Allowance for Loan Losses Charge-offs | (141) | |
Allowance for Loan Losses Recoveries | 1 | |
Allowance for Loan Losses (Credit) Provisions | (3) | 223 |
Allowance for Loan Losses Ending Balance | 331 | 138 |
Allowance for Loan Losses Ending Balance Collectively Evaluated for Impairments | $ 331 | 138 |
Consumer | Other | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Allowance for Loan Losses Beginning Balance | 1 | |
Allowance for Loan Losses Charge-offs | $ (1) |
Loans Receivable - Individually
Loans Receivable - Individually and Collectively Evaluated for Impairment By Loan Class (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | $ 252,954 | $ 255,126 |
Loans Receivable Ending Balance Individually Evaluated for Impairment | 2,245 | 2,311 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 250,709 | 252,815 |
Residential | 1-4 family | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 187,657 | 197,547 |
Loans Receivable Ending Balance Individually Evaluated for Impairment | 1,539 | 1,566 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 186,118 | 195,981 |
Residential | Home equity and HELOCs | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 4,106 | 4,383 |
Loans Receivable Ending Balance Individually Evaluated for Impairment | 279 | 308 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 3,827 | 4,075 |
Commercial | Commercial Real Estate | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 38,795 | 35,188 |
Loans Receivable Ending Balance Individually Evaluated for Impairment | 313 | 317 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 38,482 | 34,871 |
Commercial | Commercial Business | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 14,349 | 11,119 |
Loans Receivable Ending Balance Individually Evaluated for Impairment | 114 | 120 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 14,235 | 10,999 |
Construction | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 2,090 | 784 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 2,090 | 784 |
Consumer | Medical Education | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 5,953 | 6,097 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | 5,953 | 6,097 |
Consumer | Other | ||
Financing Receivable, Allowance for Credit Losses [Line Items] | ||
Loans Receivable Ending Balance | 4 | 8 |
Loans Receivable Ending Balance Collectively Evaluated for Impairment | $ 4 | $ 8 |
Loans Receivable - Summary of I
Loans Receivable - Summary of Information in Regard to Impaired Loans by Loan Portfolio Class (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Recorded Investment | $ 2,021 | $ 2,191 | |
Impaired loans by loan portfolio class with no related allowance, Unpaid Principal Balance | 2,195 | 2,328 | |
Impaired loans by loan portfolio class with an allowance, Recorded Investment | 224 | 120 | |
Impaired loans by loan portfolio class with an allowance, Unpaid Principal Balance | 227 | 121 | |
Impaired loans by loan portfolio class with an allowance, Related Allowance | 1 | 12 | |
Impaired loans by loan portfolio class, Recorded Investment | 2,245 | 2,311 | |
Impaired loans by loan portfolio class, Unpaid Principal Balance | 2,422 | 2,449 | |
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | 2,278 | $ 2,138 | |
Impaired loans by loan portfolio class with no related allowance, Interest Income Recognized | 8 | 7 | |
Impaired loans by loan portfolio class with an allowance, Average Record Investment | 139 | ||
Impaired loans by loan portfolio class with an allowance, Interest Income Recognized | 2 | ||
Impaired loans by loan portfolio class, Average Record Investment | 2,278 | 2,277 | |
Impaired loans by loan portfolio class, Interest Income Recognized | 8 | 9 | |
Residential | 1-4 family | |||
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Recorded Investment | 1,539 | 1,566 | |
Impaired loans by loan portfolio class with no related allowance, Unpaid Principal Balance | 1,692 | 1,703 | |
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | 1,552 | 1,425 | |
Residential | Home equity and HELOCs | |||
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Recorded Investment | 55 | 308 | |
Impaired loans by loan portfolio class with no related allowance, Unpaid Principal Balance | 76 | 308 | |
Impaired loans by loan portfolio class with an allowance, Recorded Investment | 224 | ||
Impaired loans by loan portfolio class with an allowance, Unpaid Principal Balance | 227 | ||
Impaired loans by loan portfolio class with an allowance, Related Allowance | 1 | ||
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | 294 | 67 | |
Commercial | Commercial Real Estate | |||
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Recorded Investment | 313 | 317 | |
Impaired loans by loan portfolio class with no related allowance, Unpaid Principal Balance | 313 | 317 | |
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | 315 | 388 | |
Impaired loans by loan portfolio class with no related allowance, Interest Income Recognized | 6 | 7 | |
Commercial | Commercial Business | |||
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Recorded Investment | 114 | ||
Impaired loans by loan portfolio class with no related allowance, Unpaid Principal Balance | 114 | ||
Impaired loans by loan portfolio class with an allowance, Recorded Investment | 120 | ||
Impaired loans by loan portfolio class with an allowance, Unpaid Principal Balance | 121 | ||
Impaired loans by loan portfolio class with an allowance, Related Allowance | $ 12 | ||
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | 117 | ||
Impaired loans by loan portfolio class with no related allowance, Interest Income Recognized | $ 2 | ||
Impaired loans by loan portfolio class with an allowance, Average Record Investment | 139 | ||
Impaired loans by loan portfolio class with an allowance, Interest Income Recognized | 2 | ||
Consumer | Medical Education | |||
Financing Receivable, Allowance for Credit Losses [Line Items] | |||
Impaired loans by loan portfolio class with no related allowance, Average Record Investment | $ 258 |
Loans Receivable - Summary of N
Loans Receivable - Summary of Nonaccrual Loans by Classes of Loan Portfolio (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Modifications [Line Items] | ||
Loans receivable, nonaccrual status | $ 3,784 | $ 3,704 |
Residential | 1-4 family | ||
Financing Receivable, Modifications [Line Items] | ||
Loans receivable, nonaccrual status | 1,656 | 1,686 |
Residential | Home equity and HELOCs | ||
Financing Receivable, Modifications [Line Items] | ||
Loans receivable, nonaccrual status | 279 | 308 |
Consumer | Medical Education | ||
Financing Receivable, Modifications [Line Items] | ||
Loans receivable, nonaccrual status | $ 1,849 | $ 1,710 |
Loans Receivable - Credit Quali
Loans Receivable - Credit Quality Indicators by Class of Loan Portfolio (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | $ 252,954 | $ 255,126 |
Pass | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 248,477 | 250,706 |
Special Mention | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 201 | 204 |
Pass | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 4,276 | 4,216 |
Residential | 1-4 family | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 187,657 | 197,547 |
Residential | Home equity and HELOCs | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 4,106 | 4,383 |
Residential | Pass | 1-4 family | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 186,001 | 195,861 |
Residential | Pass | Home equity and HELOCs | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 3,827 | 4,075 |
Residential | Pass | 1-4 family | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 1,656 | 1,686 |
Residential | Pass | Home equity and HELOCs | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 279 | 308 |
Commercial | Commercial Real Estate | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 38,795 | 35,188 |
Commercial | Commercial Business | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 14,349 | 11,119 |
Commercial | Pass | Commercial Real Estate | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 38,281 | 34,667 |
Commercial | Pass | Commercial Business | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 14,170 | 10,924 |
Commercial | Special Mention | Commercial Real Estate | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 201 | 204 |
Commercial | Pass | Commercial Real Estate | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 313 | 317 |
Commercial | Pass | Commercial Business | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 179 | 195 |
Construction | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 2,090 | 784 |
Construction | Pass | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 2,090 | 784 |
Consumer | Medical Education | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 5,953 | 6,097 |
Consumer | Other | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 4 | 8 |
Consumer | Pass | Medical Education | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 4,104 | 4,387 |
Consumer | Pass | Other | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | 4 | 8 |
Consumer | Pass | Medical Education | ||
Financing Receivable Recorded Investment [Line Items] | ||
Loans and leases receivable, gross | $ 1,849 | $ 1,710 |
Loans Receivable - Summary of S
Loans Receivable - Summary of Segments of Loan Portfolio by Aging Categories (Detail) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | $ 2,562,000 | $ 1,683,000 |
Current | 250,392,000 | 253,443,000 |
Total Loans Receivable | 252,954,000 | 255,126,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Financing Receivables, 30 to 59 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 833,000 | 468,000 |
Financing Receivables, 60 to 89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 970,000 | 147,000 |
Financing Receivables, Equal to Greater than 90 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 759,000 | 1,068,000 |
Residential | 1-4 family | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,430,000 | 818,000 |
Current | 186,227,000 | 196,729,000 |
Total Loans Receivable | 187,657,000 | 197,547,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Residential | 1-4 family | Financing Receivables, 30 to 59 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 475,000 | 365,000 |
Residential | 1-4 family | Financing Receivables, 60 to 89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 656,000 | 94,000 |
Residential | 1-4 family | Financing Receivables, Equal to Greater than 90 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 299,000 | 359,000 |
Residential | Home equity and HELOCs | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 71,000 | |
Current | 4,035,000 | 4,383,000 |
Total Loans Receivable | 4,106,000 | 4,383,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Residential | Home equity and HELOCs | Financing Receivables, 60 to 89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 71,000 | |
Commercial | Commercial Real Estate | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Current | 38,795,000 | 35,188,000 |
Total Loans Receivable | 38,795,000 | 35,188,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Commercial | Commercial Business | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Current | 14,349,000 | 11,119,000 |
Total Loans Receivable | 14,349,000 | 11,119,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Construction | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Current | 2,090,000 | 784,000 |
Total Loans Receivable | 2,090,000 | 784,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Consumer | Medical Education | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,061,000 | 865,000 |
Current | 4,892,000 | 5,232,000 |
Total Loans Receivable | 5,953,000 | 6,097,000 |
Loans Receivable >90 Days and Accruing | 0 | 0 |
Consumer | Medical Education | Financing Receivables, 30 to 59 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 358,000 | 103,000 |
Consumer | Medical Education | Financing Receivables, 60 to 89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 243,000 | 53,000 |
Consumer | Medical Education | Financing Receivables, Equal to Greater than 90 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 460,000 | 709,000 |
Consumer | Other | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Current | 4,000 | 8,000 |
Total Loans Receivable | 4,000 | 8,000 |
Loans Receivable >90 Days and Accruing | $ 0 | $ 0 |
Loans Receivable - Summary of T
Loans Receivable - Summary of Troubled Debt Restructurings on Accrual Status and Non-Accrual Status (Detail) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020USD ($)Loan | Dec. 31, 2019USD ($)Loan | |
Financing Receivable, Modifications [Line Items] | ||
Number of loans identified as TDRs | Loan | 2 | 2 |
Loans identified as TDRs | $ 251 | $ 259 |
Accrual Status | ||
Financing Receivable, Modifications [Line Items] | ||
Loans identified as TDRs | $ 251 | $ 259 |
Commercial Real Estate | ||
Financing Receivable, Modifications [Line Items] | ||
Number of loans identified as TDRs | Loan | 1 | 1 |
Loans identified as TDRs | $ 137 | $ 139 |
Commercial Real Estate | Accrual Status | ||
Financing Receivable, Modifications [Line Items] | ||
Loans identified as TDRs | $ 137 | $ 139 |
Commercial Business | ||
Financing Receivable, Modifications [Line Items] | ||
Number of loans identified as TDRs | Loan | 1 | 1 |
Loans identified as TDRs | $ 114 | $ 120 |
Commercial Business | Accrual Status | ||
Financing Receivable, Modifications [Line Items] | ||
Loans identified as TDRs | $ 114 | $ 120 |
Derivatives and Risk Manageme_3
Derivatives and Risk Management Activities - Summary of Derivatives not Designated as Hedging Instruments Recorded in Consolidated Statement of Financial Condition (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Derivatives, Fair Value [Line Items] | ||
Asset Derivatives, Fair Value | $ 2,236 | $ 1,204 |
Not Designated as Hedging Instrument | Interest Rate Lock Commitments | Mortgage banking derivatives | ||
Derivatives, Fair Value [Line Items] | ||
Asset Derivatives, Fair Value | 1,939 | 810 |
Asset Derivatives, Notional Amount | 102,349 | 25,059 |
Not Designated as Hedging Instrument | Interest Rate Lock Commitments | Other Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Liability Derivatives, Fair Value | 32 | 25 |
Liability Derivatives, Notional Amount | 4,815 | 3,820 |
Not Designated as Hedging Instrument | Forward Loan Sales Commitments | Mortgage banking derivatives | ||
Derivatives, Fair Value [Line Items] | ||
Asset Derivatives, Fair Value | 297 | 389 |
Asset Derivatives, Notional Amount | 7,266 | 11,036 |
Not Designated as Hedging Instrument | Forward Loan Sales Commitments | Other Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Liability Derivatives, Fair Value | 87 | 45 |
Liability Derivatives, Notional Amount | 8,863 | 10,595 |
Not Designated as Hedging Instrument | To Be Announced securities ("TBAs") | Mortgage banking derivatives | ||
Derivatives, Fair Value [Line Items] | ||
Asset Derivatives, Fair Value | 5 | |
Asset Derivatives, Notional Amount | 3,500 | |
Not Designated as Hedging Instrument | To Be Announced securities ("TBAs") | Other Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Liability Derivatives, Fair Value | 655 | 56 |
Liability Derivatives, Notional Amount | $ 26,000 | $ 24,500 |
Derivatives and Risk Manageme_4
Derivatives and Risk Management Activities - Summary of Amounts Recorded in Consolidated Statements of Income for Derivative Instruments not Designated as Hedging Instruments (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain/(Loss) from derivative instruments | $ 384 | $ 395 |
Interest Rate Lock Commitments | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain/(Loss) from derivative instruments | 1,122 | 453 |
Forward Loan Sales Commitments | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain/(Loss) from derivative instruments | (134) | (14) |
TBA Securities | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain/(Loss) from derivative instruments | $ (604) | $ (44) |
Fair Value Presentation - Fair
Fair Value Presentation - Fair Value for Assets Required to be Measured and Reported at Fair Value on a Recurring Basis (Detail) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | $ 23,200,000 | $ 21,156,000 |
Loans held for sale, at fair value | 37,368,000 | 37,876,000 |
Asset Derivatives | 2,236,000 | 1,204,000 |
U.S. Governmental securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 422,000 | 436,000 |
Corporate notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 9,244,000 | 5,569,000 |
Collateralized mortgage obligations - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 6,187,000 | 6,464,000 |
Mortgage-backed securities - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 3,963,000 | 4,063,000 |
Municipal securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 2,118,000 | 2,117,000 |
Bank CDs | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 1,266,000 | 2,507,000 |
Fair Value, Measurements, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Loans held for sale, at fair value | 37,368,000 | 37,876,000 |
Assets measured at fair value | 62,804,000 | 60,236,000 |
Fair Value, Measurements, Recurring | U.S. Governmental securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 422,000 | 436,000 |
Fair Value, Measurements, Recurring | Corporate notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 9,244,000 | 5,569,000 |
Fair Value, Measurements, Recurring | Collateralized mortgage obligations - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 6,187,000 | 6,464,000 |
Fair Value, Measurements, Recurring | Mortgage-backed securities - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 3,963,000 | 4,063,000 |
Fair Value, Measurements, Recurring | Municipal securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 2,118,000 | 2,117,000 |
Fair Value, Measurements, Recurring | Forward Loan Sales Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 297,000 | 389,000 |
Fair Value, Measurements, Recurring | TBA Securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 5,000 | |
Fair Value, Measurements, Recurring | Interest Rate Lock Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 1,939,000 | 810,000 |
Fair Value, Measurements, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Loans held for sale, at fair value | 37,368,000 | 37,876,000 |
Assets measured at fair value | 57,832,000 | 56,367,000 |
Fair Value, Measurements, Recurring | Level 2 | U.S. Governmental securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 422,000 | 436,000 |
Fair Value, Measurements, Recurring | Level 2 | Corporate notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 6,211,000 | 2,510,000 |
Fair Value, Measurements, Recurring | Level 2 | Collateralized mortgage obligations - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 6,187,000 | 6,464,000 |
Fair Value, Measurements, Recurring | Level 2 | Mortgage-backed securities - agency residential | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 3,963,000 | 4,063,000 |
Fair Value, Measurements, Recurring | Level 2 | Municipal securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 2,118,000 | 2,117,000 |
Fair Value, Measurements, Recurring | Level 2 | Forward Loan Sales Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 297,000 | 389,000 |
Fair Value, Measurements, Recurring | Level 2 | TBA Securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 5,000 | |
Fair Value, Measurements, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value | 4,972,000 | 3,869,000 |
Fair Value, Measurements, Recurring | Level 3 | Corporate notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 3,033,000 | 3,059,000 |
Fair Value, Measurements, Recurring | Level 3 | Interest Rate Lock Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Asset Derivatives | 1,939,000 | 810,000 |
Fair Value, Measurements, Recurring | Bank CDs | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | 1,266,000 | 2,507,000 |
Fair Value, Measurements, Recurring | Bank CDs | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available for sale | $ 1,266,000 | $ 2,507,000 |
Fair Value Presentation - Fai_2
Fair Value Presentation - Fair Value for Liabilities Required to be Measured and Reported at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | $ 774 | $ 126 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 742 | 101 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 32 | 25 |
Forward Loan Sales Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 87 | 45 |
Forward Loan Sales Commitments | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 87 | 45 |
TBA Securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 655 | 56 |
TBA Securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 655 | 56 |
Interest Rate Lock Commitments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | 32 | 25 |
Interest Rate Lock Commitments | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Liability Derivatives | $ 32 | $ 25 |
Fair Value Presentation - Chang
Fair Value Presentation - Change in Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) - Level 3 - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Corporate notes | ||
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Beginning Balance | $ 3,059 | $ 494 |
Total gains (unrealized): Included in other comprehensive income | (26) | (2) |
Ending Balance | 3,033 | 492 |
Change in unrealized gains for the period included other comprehensive income for assets held as of March 31, 2020 | 26 | |
IRLC - Asset | ||
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Beginning Balance | 810 | 218 |
Total gains or (losses) included in earnings and held at reporting date | 1,129 | 462 |
Ending Balance | 1,939 | 680 |
Change in unrealized gains or (losses) for the period included in earnings (or changes in net assets) for assets held as of March 31, 2020 | 1,129 | |
IRLC - Liability | ||
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Beginning Balance | (25) | (18) |
Total gains or (losses) included in earnings and held at reporting date | (7) | (9) |
Ending Balance | (32) | $ (27) |
Change in unrealized gains or (losses) for the period included in earnings (or changes in net assets) for assets held as of March 31, 2020 | $ (7) |
Fair Value Presentation - Addit
Fair Value Presentation - Additional Information (Detail) | Mar. 31, 2020USD ($)$ / shares | Dec. 31, 2019USD ($) |
Fair Value Measurement Nonrecurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value | $ 0 | $ 0 |
Corporate notes | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value | 3,000,000 | |
Corporate notes | Level 3 | Pricing Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value | $ 1,000,000 | |
Corporate notes | Level 3 | Pricing Model | Minimum | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Weighted average rate | $ / shares | 92.37 | |
Corporate notes | Level 3 | Pricing Model | Maximum | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Weighted average rate | $ / shares | 104.66 | |
Corporate notes | Level 3 | Market Comparable Securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value | $ 2,000,000 | |
Weighted average rate | $ / shares | 102 | |
Interest Rate Lock Commitments | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Net derivative assets and liabilities | $ 1,900,000 | |
Interest Rate Lock Commitments | Level 3 | Minimum | Pull-through Rates | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Weighted average rate | 0.25 | |
Interest Rate Lock Commitments | Level 3 | Maximum | Pull-through Rates | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Weighted average rate | 0.98 |
Fair Value Presentation - Signi
Fair Value Presentation - Significant Unobservable Inputs for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Level 3 $ in Thousands | Mar. 31, 2020USD ($)$ / shares |
Corporate notes | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair value | $ | $ 3,000 |
Corporate notes | Pricing Model | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair value | $ | $ 1,000 |
Corporate notes | Pricing Model | Minimum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | $ / shares | 92.37 |
Corporate notes | Pricing Model | Maximum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | $ / shares | 104.66 |
Corporate notes | Market Comparable Securities | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair value | $ | $ 2,000 |
Weighted average rate | $ / shares | 102 |
IRLC | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value | $ | $ 1,900 |
IRLC | Pull-through Rates | Minimum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | 0.25 |
IRLC | Pull-through Rates | Maximum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | 0.98 |
Fair Value, Measurements, Recurring | Corporate notes | Pricing Model | Market Quotes | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair value | $ | $ 1,033 |
Weighted average rate | $ / shares | 101.24 |
Fair Value, Measurements, Recurring | Corporate notes | Pricing Model | Market Quotes | Minimum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | $ / shares | 92.37 |
Fair Value, Measurements, Recurring | Corporate notes | Pricing Model | Market Quotes | Maximum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | $ / shares | 104.66 |
Fair Value, Measurements, Recurring | Corporate notes | Market Comparable Securities | Market Quotes | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair value | $ | $ 2,000 |
Weighted average rate | $ / shares | 102 |
Fair Value, Measurements, Recurring | IRLC | Discounted Cash Flows | Pull-through Rates | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value | $ | $ 1,939 |
Weighted average rate | 0.77 |
Fair Value, Measurements, Recurring | IRLC | Discounted Cash Flows | Pull-through Rates | Minimum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | 0.25 |
Fair Value, Measurements, Recurring | IRLC | Discounted Cash Flows | Pull-through Rates | Maximum | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Weighted average rate | 0.98 |
Fair Value Presentation - Carry
Fair Value Presentation - Carrying Amount for Class of Assets and Liabilities and Fair Value for Certain Financial Instruments Not Required to be Measured or Reported at Fair Value (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | |
Assets: | |||
Equity securities | $ 500 | $ 500 | |
Carrying Amount | |||
Assets: | |||
Cash and cash equivalents | 20,515 | 20,625 | |
Equity securities | 500 | 500 | |
Loans receivable, net | [1] | 252,704 | 255,032 |
Bank-owned life insurance | 6,293 | 6,255 | |
Restricted investment in bank stock | 1,751 | 1,552 | |
Accrued interest receivable | 1,112 | 967 | |
Liabilities: | |||
Deposits | 278,185 | 283,767 | |
Advances from the FHLB | 32,000 | 27,000 | |
Advances from borrowers for taxes and insurance | 1,936 | 2,138 | |
Accrued interest payable | 186 | 305 | |
Estimated Fair Value | |||
Assets: | |||
Cash and cash equivalents | 20,515 | 20,625 | |
Equity securities | 500 | 500 | |
Loans receivable, net | [1] | 260,389 | 254,884 |
Bank-owned life insurance | 6,293 | 6,255 | |
Restricted investment in bank stock | 1,751 | 1,552 | |
Accrued interest receivable | 1,112 | 967 | |
Liabilities: | |||
Deposits | 278,599 | 284,055 | |
Advances from the FHLB | 32,692 | 27,333 | |
Advances from borrowers for taxes and insurance | 1,936 | 2,138 | |
Accrued interest payable | 186 | 305 | |
Level 1 | |||
Assets: | |||
Cash and cash equivalents | 20,515 | 20,625 | |
Bank-owned life insurance | 6,293 | 6,255 | |
Restricted investment in bank stock | 1,751 | 1,552 | |
Accrued interest receivable | 1,112 | 967 | |
Liabilities: | |||
Deposits | 216,372 | 215,471 | |
Advances from the FHLB | 5,000 | ||
Advances from borrowers for taxes and insurance | 1,936 | 2,138 | |
Accrued interest payable | 186 | 305 | |
Level 2 | |||
Liabilities: | |||
Deposits | 62,227 | 68,584 | |
Advances from the FHLB | 27,692 | 27,333 | |
Level 3 | |||
Assets: | |||
Equity securities | 500 | 500 | |
Loans receivable, net | [1] | $ 260,389 | $ 254,884 |
[1] | In accordance with the prospective adoption of ASU No. 2016-01, the fair value of the loans as of September 30, 2019 and June 30, 2019 were measured using an exit price notion. |
Changes in and Reclassificati_3
Changes in and Reclassifications out of Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in Component of Accumulated Other Comprehensive Income (Loss), Net of Tax (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Beginning balance | $ 33,599 | $ 31,411 | |
Unrealized holding gain on available-for-sale securities before reclassification | 89 | 249 | |
Amount reclassified for investment securities gains included in net income | [1] | (3) | |
Other comprehensive income | 89 | 246 | |
Ending balance | 33,813 | 31,809 | |
Net Unrealized Holding Gains on Available-for-sales Securities | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Beginning balance | [2] | (18) | (548) |
Unrealized holding gain on available-for-sale securities before reclassification | [2] | 89 | 249 |
Amount reclassified for investment securities gains included in net income | [2] | (3) | |
Other comprehensive income | [2] | 89 | 246 |
Ending balance | [2] | $ 71 | $ (302) |
[1] | Amounts are included in gain on sale of available-for-sale securities on the Consolidated Statements of Income as a separate element within non-interest income. Income tax expense is included in the Consolidated Statements of Income. | ||
[2] | All amounts are net of tax. Related tax expense or benefit is calculated using an income tax rate of approximately 29.5% and 28.2% for the three months ended March 31, 2020 and 2019, respectively. |
Changes in and Reclassificati_4
Changes in and Reclassifications out of Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in Component of Accumulated Other Comprehensive Income (Loss), Net of Tax (Parenthetical) (Detail) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Stockholders Equity Note [Abstract] | ||
Income tax rate | 29.50% | 28.20% |
Changes in and Reclassificati_5
Changes in and Reclassifications out of Accumulated Other Comprehensive Income (Loss) - Reclassifications out of AOCI by Component (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items] | |||
Gain on sale of investment securities net, before tax | $ 0 | $ (4) | |
Gain on sale of investment securities net, Net of tax | [1] | 3 | |
Gain on Sale of Investment Securities, net | Amount Reclassified from Accumulated Other Comprehensive Income (Loss) | |||
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items] | |||
Gain on sale of investment securities net, before tax | [2],[3] | 4 | |
Gain on sale of investment securities net, Income tax expense | [2],[3] | (1) | |
Gain on sale of investment securities net, Net of tax | [2],[3] | $ 3 | |
[1] | Amounts are included in gain on sale of available-for-sale securities on the Consolidated Statements of Income as a separate element within non-interest income. Income tax expense is included in the Consolidated Statements of Income. | ||
[2] | Amounts in parentheses indicate debits. | ||
[3] | For additional details related to unrealized gains on investment securities and related amounts reclassified from accumulated other comprehensive loss, See Note 2, “Investment securities.” |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Detail) - shares | 3 Months Ended | |||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Earnings Per Share Basic [Line Items] | ||||
Stock options outstanding | 216,400 | 198,000 | 218,000 | 188,000 |
Share vested and exercisable | 30,080 | 0 | ||
Restricted Stock | ||||
Earnings Per Share Basic [Line Items] | ||||
Restricted stock shares outstanding | 87,000 | 77,000 | ||
Share vested and exercisable other than option | 12,320 | 0 | ||
Stock outstanding not included in computation of diluted net income per share | 65,981 | |||
Stock Options | ||||
Earnings Per Share Basic [Line Items] | ||||
Stock outstanding not included in computation of diluted net income per share | 216,400 | 198,000 |
Earnings Per Share - Computatio
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Net Income | $ 149,000 | $ 62,000 |
Weighted average number of shares issued | 2,270,180 | 2,261,258 |
Less weighted average number of treasury shares | (2,487) | |
Less weighted average number of unearned ESOP shares | (146,954) | (155,682) |
Less weighted average number of unvested restricted stock awards | (67,050) | (75,207) |
Basic weighted average shares outstanding | 2,053,689 | 2,030,369 |
Diluted weighted average shares outstanding | 2,053,764 | 2,030,369 |
Net income per share: | ||
Basic | $ 0.07 | $ 0.03 |
Diluted | $ 0.07 | $ 0.03 |
Stock Options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Add dilutive effect of stock | 75 |
Employee Benefits - Additional
Employee Benefits - Additional Information (Detail) - 2018 Equity Incentive Plan - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Jun. 13, 2018 | |
Defined Contribution Plan Disclosure [Line Items] | |||
Maximum number of shares authorized | 305,497 | ||
Share based compensation, number of shares available for grant | 497 | ||
Stock option expense | $ 15,000 | $ 14,000 | |
Restricted stock expense | 47,000 | $ 45,000 | |
Stock Options | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Maximum number of shares authorized | 218,212 | ||
Total unrecognized compensation cost | $ 323,000 | ||
Restricted Stock Awards or Restricted Stock Units | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Maximum number of shares authorized | 87,285 | ||
Incentive and Non-Qualified Stock Options | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Share based compensation, number of shares available for grant | 212 | ||
Restricted Stock Awards | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Share based compensation, number of shares available for grant | 285 | ||
Restricted Shares and Stock Options | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Share based compensation, vesting period | 7 years | ||
Non Vested Restricted Stock Outstanding | |||
Defined Contribution Plan Disclosure [Line Items] | |||
Expected future compensation expense | $ 984,000 |
Employee Benefits - Summary of
Employee Benefits - Summary of Stock Option Activity (Detail) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Options | ||||
Outstanding, balance | 218,000 | 188,000 | 188,000 | |
Granted | 10,000 | |||
Exercised | (1,600) | |||
Outstanding, balance | 216,400 | 198,000 | 218,000 | 188,000 |
Exercisable | 30,080 | |||
Weighted-Average Exercise Price | ||||
Outstanding, balance | $ 14.92 | $ 14.80 | $ 14.80 | |
Granted | 15.28 | |||
Exercised | 14.82 | |||
Outstanding, balance | 14.93 | $ 14.82 | $ 14.92 | $ 14.80 |
Exercisable | $ 14.83 | |||
Weighted-Average Remaining Contractual Life (in years) | ||||
Outstanding, balance | 8 years 4 months 24 days | 9 years 7 months 6 days | 8 years 7 months 6 days | 9 years 4 months 24 days |
Granted | 9 years 10 months 25 days | |||
Exercisable | 8 years 3 months 19 days | |||
Average Intrinsic Value | ||||
Outstanding, balance | $ 253,440 | $ 452,400 | $ 33,840 |
Employee Benefits - Summary o_2
Employee Benefits - Summary of Restricted Stock Activity (Detail) - Restricted stock awards - $ / shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Number of Shares | ||
Non-vested, Jan 1 | 75,320 | 73,000 |
Vested | (640) | |
Granted | 4,000 | |
Non-vested at March 31 | 74,680 | 77,000 |
Weighted-Average Grant Date Fair Value | ||
Non-vested, Jan 1 | $ 14.97 | $ 14.80 |
Vested | 15.21 | |
Granted | 15.21 | |
Non-vested at March 31 | $ 14.97 | $ 14.82 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Related Party Transaction [Line Items] | ||
Fees for customer services | $ 39,000 | $ 30,000 |
Business Consulting Agreement | ||
Related Party Transaction [Line Items] | ||
Business consulting agreement termination date | Dec. 31, 2019 | |
Director | Business Consulting Agreement | ||
Related Party Transaction [Line Items] | ||
Consulting fees | 15,000 | |
Competitive Rate of Return and FDIC Insurance | ||
Related Party Transaction [Line Items] | ||
Company held deposits for related parties | $ 11,900,000 | |
Fees for customer services | $ 2,000 | $ 5,000 |
Revenue Recognition - Additiona
Revenue Recognition - Additional Information (Detail) | Mar. 31, 2020USD ($) |
Maximum | |
Disaggregation of Revenue [Line Items] | |
FDIC insurance amount | $ 250,000 |
Revenue Recognition - Summary o
Revenue Recognition - Summary of Noninterest Income (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Non-Interest Income | ||
Total Non-Interest Income (in-scope of Topic 606) | $ 39 | $ 30 |
Total Non-Interest Income (out-scope of Topic 606) | 2,105 | 956 |
Total Non-Interest Income | 2,144 | 986 |
Increase in cash surrender value of bank-owned life insurance | 38 | 39 |
Gain on sale of loans, net | 1,629 | 890 |
Gain on sale of available-for-sale securities, net | 4 | |
Gain from derivative instruments | 384 | 395 |
Change in fair value of loans held-for-sale | 6 | (376) |
Other | 48 | 4 |
Fee income | ||
Non-Interest Income | ||
Total Non-Interest Income (in-scope of Topic 606) | 3 | 5 |
Insufficient fund fees | ||
Non-Interest Income | ||
Total Non-Interest Income (in-scope of Topic 606) | 17 | 12 |
Other service charges | ||
Non-Interest Income | ||
Total Non-Interest Income (in-scope of Topic 606) | 17 | 11 |
ATM interchange fee income | ||
Non-Interest Income | ||
Total Non-Interest Income (in-scope of Topic 606) | $ 2 | $ 2 |
Leases - Consolidated Statement
Leases - Consolidated Statement of Financial Condition Classification of ROU Assets and Lease Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Operating lease right-of-use assets | $ 6,187 | $ 5,979 |
Operating lease liabilities | $ 6,296 | $ 6,023 |
Leases - Summary of Weighted Av
Leases - Summary of Weighted Average Lease Term and Discount Rate (Detail) | Mar. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Operating Lease,Weighted-average remaining lease term | 12 years 6 months | 12 years 8 months 12 days |
Operating Lease,Weighted-average discount rate | 2.29% | 2.34% |
Leases - Components of Lease Ex
Leases - Components of Lease Expense (Detail) $ in Thousands | 3 Months Ended |
Mar. 31, 2020USD ($) | |
Leases [Abstract] | |
Operating lease cost | $ 132 |
Short-term lease cost | 17 |
Total | $ 149 |
Leases - Schedule of Future Min
Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Within one year | $ 536 | $ 440 |
After one but within two years | 656 | 632 |
After two but within three years | 623 | 583 |
After three but within four years | 633 | 594 |
After four but within five years | 616 | 596 |
After five years | 4,210 | 4,164 |
Total future minimum lease payments | 7,274 | 7,009 |
Amounts Representing Interest | (978) | (986) |
Present Value of Net Future Minimum Lease Payments | $ 6,296 | $ 6,023 |